

Regulation of cerebral blood flow by arterial PCO₂ independent of metabolic acidosis at 5,050 m

Caldwell, Hannah G ; Smith, Kurt J; Lewis, Nia C S; Hoiland, Ryan L; Willie, Chris K; Lucas, Sam; Stemberge, Mike; Burgess, Keith R; MacLeod, David B; Ainslie, P.N.

DOI:
[10.1113/JP281446](https://doi.org/10.1113/JP281446)

License:
Other (please specify with Rights Statement)

Document Version
Peer reviewed version

Citation for published version (Harvard):
Caldwell, HG, Smith, KJ, Lewis, NCS, Hoiland, RL, Willie, CK, Lucas, S, Stemberge, M, Burgess, KR, MacLeod, DB & Ainslie, PN 2021, 'Regulation of cerebral blood flow by arterial PCO₂ independent of metabolic acidosis at 5,050 m', *The Journal of Physiology*, vol. 599, no. 14, pp. 3513-3530. <https://doi.org/10.1113/JP281446>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This is the peer reviewed version of the following article: Caldwell, H.G., Smith, K.J., Lewis, N.C., Hoiland, R.L., Willie, C.K., Lucas, S.J., Stemberge, M., Burgess, K.R., MacLeod, D.B. and Ainslie, P.N. (2021), Regulation of cerebral blood flow by arterial PCO₂ independent of metabolic acidosis at 5,050 m. *J Physiol.*, which has been published in final form at <https://doi.org/10.1113/JP281446>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

The Journal of Physiology

<https://jp.msubmit.net>

JP-RP-2021-281446R2

Title: Regulation of cerebral blood flow by arterial PCO₂ independent of metabolic acidosis at 5,050 m

Authors: Hannah Caldwell

Kurt Smith

Nia Lewis

Ryan Hoiland

Christopher Willie

Samuel Lucas

Mike Stembridge

Keith Burgess

David MacLeod

Philip Ainslie

Author Conflict: No competing interests declared

Author Contribution: Hannah Caldwell: Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work Kurt Smith: Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work Nia Lewis: Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work

Disclaimer: This is a confidential document.

Ryan Hoiland: Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work
Christopher Willie: Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work
Samuel Lucas: Conception or design of the work; Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work
Mike Stenbridge: Conception or design of the work; Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work
Keith Burgess: Conception or design of the work; Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work
David MacLeod: Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work
Philip Ainslie: Conception or design of the work; Acquisition or analysis or interpretation of data for the work; Drafting the work or revising it critically for important intellectual content; Final approval of the version to be published; Agreement to be accountable for all aspects of the work

Running Title: ACID-BASE BALANCE AND CEREBRAL BLOOD FLOW AT HIGH-ALTITUDE

Dual Publication: No

Funding: Canada Research Chairs (Chaires de recherche du Canada): Philip N Ainslie, F11-02423

ACID-BASE BALANCE AND CEREBRAL BLOOD FLOW AT HIGH-ALTITUDE

Regulation of cerebral blood flow by arterial PCO₂ independent of metabolic acidosis at 5,050 m

Hannah G. Caldwell¹, Kurt J. Smith², Nia C.S. Lewis¹, Ryan L. Hoiland^{3,4}, Christopher K. Willie¹, Samuel J.E. Lucas^{5,6}, Michael Stembridge⁷, Keith R. Burgess^{8,9}, David B. MacLeod¹⁰, Philip N. Ainslie¹

¹*Centre for Heart, Lung and Vascular Health, School of Health and Exercise Sciences, University of British Columbia Okanagan, Kelowna, BC, Canada, V1V 1V7*

²*Integrative Physiology Laboratory, Department of Kinesiology and Nutrition, University of Illinois Chicago, Chicago, IL, USA*

³*Department of Anesthesiology, Pharmacology and Therapeutics, Vancouver General Hospital, West 12th Avenue, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9*

⁴*Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, BC, Canada, V6T 1Z4*

⁵*Department of Physiology, University of Otago, Dunedin, New Zealand.*

⁶*School of Sport, Exercise and Rehabilitation Sciences & Centre for Human Brain Health, University of Birmingham, Birmingham, United Kingdom*

⁷*Cardiff School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff, UK*

⁸*Peninsula Sleep Clinic, Sydney, New South Wales, Australia*

⁹*Department of Medicine, University of Sydney, Sydney, New South Wales, Australia*

¹⁰*Human Pharmacology and Physiology Lab, Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA, 27708*

Corresponding author: Hannah G. Caldwell, Centre for Heart, Lung and Vascular Health, School of Health and Exercise Sciences, University of British Columbia – Okanagan, 3333 University Way, Kelowna, British Columbia, Canada, V1V 1V7
Email address: hannahcaldwell@alumni.ubc.ca

Summary:

- We investigated the influence of arterial PCO_2 (PaCO_2) with and without experimentally altered pH on cerebral blood flow (CBF) regulation at sea level and with acclimatization to 5,050 m.
- At sea level and high-altitude, we assessed stepwise alterations in PaCO_2 following metabolic acidosis (via two days of oral acetazolamide; ACZ) with and without acute restoration of pH (via intravenous sodium bicarbonate; ACZ+ HCO_3^-).
- Total resting CBF was unchanged between trials within each altitude even though arterial pH and $[\text{HCO}_3^-]$ (i.e., buffering capacity) were effectively altered.
- The cerebrovascular responses to changes in arterial $[\text{H}^+]/\text{pH}$ were consistent with the altered relationship between PaCO_2 and $[\text{H}^+]/\text{pH}$ following ACZ at high-altitude (i.e., leftward x-intercept shifts).
- Absolute cerebral blood velocity (CBV) and the sensitivity of CBV to PaCO_2 was unchanged between trials at high-altitude, indicating that CBF is acutely regulated by PaCO_2 rather than *arterial* pH.

Key Words: Cerebral blood flow, acid-base balance, high-altitude, CO_2 reactivity, acetazolamide, sodium bicarbonate, metabolic acidosis

ABSTRACT

Alterations in acid-base balance with progressive acclimatization to high-altitude have been well-established; however, how respiratory alkalosis and resultant metabolic compensation interact to regulate cerebral blood flow (CBF) is uncertain. We addressed this via three separate experimental trials at sea level and following partial acclimatization (14 to 20 days) at 5,050 m; involving: 1) resting acid-base balance (control); 2) following metabolic acidosis via two days of oral acetazolamide at 250 mg every 8 hours (ACZ; pH: $\Delta -0.07 \pm 0.04$ and base excess: $\Delta -5.7 \pm 1.9$ mEq·l⁻¹, trial effects: P<0.001 and P<0.001, respectively); and 3) after acute normalization of arterial acidosis via intravenous sodium bicarbonate (ACZ+HCO₃⁻; pH: $\Delta -0.01 \pm 0.04$ and base excess: $\Delta -1.5 \pm 2.1$ mEq·l⁻¹, trial effects: P=1.000 and P=0.052, respectively). Within each trial, we utilized transcranial Doppler ultrasound to assess the cerebral blood velocity (CBV) response to stepwise alterations in arterial PCO₂ (PaCO₂); i.e., cerebrovascular CO₂ reactivity. Resting CBF (via Duplex ultrasound) was unaltered between trials within each altitude, indicating that respiratory compensation (i.e., $\Delta -3.4 \pm 2.3$ mmHg PaCO₂, trial effect: P<0.001) was sufficient to offset any elevations in CBF induced via the ACZ-mediated metabolic acidosis. Between trials at high-altitude, we observed consistent *leftward* shifts in both the PaCO₂-pH and CBV-pH responses across the CO₂ reactivity tests with experimentally *reduced* arterial pH via ACZ. When indexed against PaCO₂ – rather than pH – the absolute CBV and sensitivity of CBV-PaCO₂ was unchanged between trials at high-altitude. Taken together, following acclimatization, CO₂-mediated changes in cerebrovascular tone rather than *arterial* [H⁺]/pH is integral to CBF regulation at high-altitude.

Word Count: 250/250

INTRODUCTION

The cerebral vasculature is exceptionally sensitive to alterations in the partial pressure of arterial carbon dioxide (PaCO_2) (Hoiland *et al.*, 2019) such that increases and decreases in PaCO_2 (i.e., hyper- and hypocapnia) rapidly increase and decrease cerebral blood flow (CBF), respectively (Kety & Schmidt, 1948). The integrative relationship between PaCO_2 and pH on CBF regulation acts to stabilize CO_2 gradients and thus regulate pH across the blood-brain-barrier; that is, alterations in PaCO_2 provoke inverse changes in pH (Fencl *et al.*, 1969; reviewed in: Hoiland *et al.*, 2019). Although acute changes in respiratory acidosis/alkalosis elicit changes in interstitial/intracellular pH (Fencl *et al.*, 1966; Betz & Heuser, 1967; Arieff *et al.*, 1976), the CSF pH is stable across *chronic* metabolic acidosis and alkalosis to support a narrow range of extravascular pH levels irrespective of marked changes in arterial pH (Mitchell *et al.*, 1965; Fencl *et al.*, 1969; reviewed in: Siesjö, 1972). It is noteworthy that PaCO_2 -mediated cerebrovascular responses are dependent on the rapid diffusion of CO_2 across the vascular wall to alter perivascular extracellular pH rather than direct changes in arterial pH *per se* (Wolff & Lennox, 1930; Lambertsen *et al.*, 1961; Severinghaus & Lassen, 1967; Betz & Heuser, 1967; Wahl *et al.*, 1970; Kontos *et al.*, 1977b; 1977a). With this view, at least in the context of acute metabolic alkalosis, CBF regulation is dependent on PaCO_2 rather than arterial pH *per se* (Caldwell *et al.*, 2021); however, whether this finding is consistent following acclimatization to high-altitude, where metabolic compensation for the prevailing respiratory alkalosis occurs, merits investigation.

Alterations in acid-base balance during high-altitude exposure are well-reported (Dempsey *et al.*, 1974; Forster *et al.*, 1975; Weiskopf *et al.*, 1976). With ascent to high-altitude, the initial hypoxic ventilatory response reduces PaCO_2 and arterial $[\text{H}^+]$ (i.e., respiratory alkalosis) and, as such, arterial/CSF pH is elevated (Severinghaus *et al.*, 1963; reviewed in: Hoiland *et al.*, 2018). This respiratory alkalosis is partially compensated by renal excretion of bicarbonate (HCO_3^-) that begins in the first 1-2 days across progressive acclimatization; e.g., 1-2 weeks (Gledhill *et al.*, 1975; Dempsey *et al.*, 1978; Krapf *et al.*, 1991). Acetazolamide (ACZ) is a carbonic anhydrase inhibitor that accelerates the acclimatization process (Bärtsch & Swenson, 2013; Swenson, 2014) by increasing ventilation and accelerated renal excretion of HCO_3^- to induce metabolic acidosis (Kronenberg & Cain, 1968; Teppema *et al.*, 2010). At sea level,

studies indicate that the initial marked 40-50% increase in resting CBF mediated by transient extracellular acidosis provoked by a single oral dose of 1,000 mg ACZ is normalized within two days of chronic ACZ (10 days of 500 mg twice daily) via respiratory compensation; i.e., progressive 30% reduction in alveolar PCO_2 (Lassen *et al.*, 1987; Friberg *et al.*, 1990). These results emphasize that the influence of ACZ on CBF regulation is likely dependent on the countervailing balance between: 1) metabolic acidosis-induced cerebral *vasodilation* (Fencl *et al.*, 1969; Kontos *et al.*, 1977b); and 2) hyperventilation-induced hypocapnic cerebral *vasoconstriction* (Willie *et al.*, 2012; 2015).

According to the Henderson-Hasselbalch equation: $\text{pH} = 6.1 + \log [\text{HCO}_3^-] / (0.0314 \times \text{PCO}_2)$ (Hasselbalch, 1916), reductions in arterial $[\text{HCO}_3^-]$ at high-altitude would decrease buffering capacity; that is, a given change in PaCO_2 will elicit a larger change in arterial $[\text{H}^+]/\text{pH}$ (Siesjö, 1972). As such, appropriate changes in cerebrovascular CO_2 reactivity (i.e., change in CBF for a given change in PaCO_2) with respect to changes in buffering capacity are essential to tightly regulate cerebral interstitial pH to support critical enzymatic function (Fencl *et al.*, 1966; reviewed in: Fencl & Rossing, 1989). Likewise, if the cerebral vasculature is acutely regulated by PaCO_2 *per se* (Schieve & Wilson, 1953; Lambertsen *et al.*, 1961; Caldwell *et al.*, 2021), then alterations in the buffering capacity of PaCO_2 and $[\text{H}^+]/\text{pH}$ at high-altitude will result in consistent changes with CBF and $[\text{H}^+]/\text{pH}$ (i.e., rightward x-intercept shifts). Previous reports indicate either attenuated (Ainslie *et al.*, 2008), unchanged (Ainslie & Burgess, 2008; Rupp *et al.*, 2014; Willie *et al.*, 2015), or augmented (Fan *et al.*, 2010; Lucas *et al.*, 2011; Flück *et al.*, 2015) cerebrovascular CO_2 reactivity with initial ascent and partial acclimatization to high-altitude. These disparate findings are likely attributable to differences in approaches to index cerebrovascular CO_2 reactivity, severity of altitude, ascent profile, stage of acclimatization, and the prevailing compensatory changes in the buffering capacity of PaCO_2 and $[\text{H}^+]/\text{pH}$ at high-altitude (Crawford & Severinghaus, 1978; Mathew *et al.*, 1983; Fan *et al.*, 2015).

This study investigated the interaction between acid-base balance on resting CBF and cerebrovascular CO_2 reactivity via three separate experimental trials at sea level and following partial acclimatization (14 to 20 days) at 5,050 m, involving: 1) resting acid-base balance (control); 2) following two days of oral acetazolamide dosing (ACZ; 250 mg per 8 hours); and 3) after acute normalization of arterial pH (ACZ+ HCO_3^-). To account for the relative metabolic acidosis elicited by ACZ, we utilized an intravenous infusion of sodium bicarbonate (NaHCO_3^-)

to normalize arterial pH with a partial restoration of PaCO_2 . At least at sea level, intravenous NaHCO_3^- infusion provokes progressive increases in PaCO_2 via respiratory suppression (Gesell *et al.*, 1930; Shock & Hastings, 1935; Bernthal, 1937; Hesser, 1949; Singer *et al.*, 1956) to partially compensate for the associated metabolic alkalosis; however, this elevated *arterial* pH is only reflected in the CSF/extracellular pH after several hours (Robin *et al.*, 1958; Bradley & Semple, 1962; Hornbein & Pavlin, 1975; Nattie & Romer, 1978; Abeysekara *et al.*, 2012). Whether these compensatory changes in respiration occur at high-altitude and their resultant influence on cerebrovascular regulation has not been reported. We hypothesized that CBF regulation at rest would correspond to changes in PaCO_2 (e.g., respiratory compensation) rather than arterial pH (e.g., pharmacologically induced) between trials at sea level and high-altitude. Additionally, we hypothesized that the cerebrovascular responses to changes in $[\text{H}^+]/\text{pH}$ would be consistent with the altered relationship between PaCO_2 and $[\text{H}^+]/\text{pH}$ between altitudes and within the acute acid-base trials.

METHODS

Ethical Approval

The study was approved by the Clinical Ethical Review Board at the University of British Columbia (H11-03287) and the Nepal Health Medical Research Council. All experimental procedures were conducted in accordance with the Declaration of Helsinki (except registration in a database). Following verbal and written explanation of the study, written informed consent was provided by all volunteers.

Participants

Eleven healthy adults ($n = 9$ males/ 2 females; 28 ± 6 years, 175 ± 6 cm, 77 ± 14 kg, 25 ± 4 kg/m^2) participated in this study at sea level (SL). Ten healthy adults ($n = 7$ males/ 3 females; 29 ± 5 years, 175 ± 6 cm, 74 ± 12 kg, 24 ± 4 kg/m^2) participated in this study at high-altitude (HA). Participants had no history of cardiovascular, cerebrovascular, or respiratory disease and were not taking any cardiovascular medications.

Experimental Overview

This study was part of a larger research expedition conducted in April-June 2012. As such, participants were involved in a number of studies conducted during pre-testing in Kelowna and during the 3 weeks at the Ev-K2-CNR Pyramid Laboratory. The recovery time between the various testing sessions was managed to avoid any cross-over effects between multiple experiments (e.g., >48 hours between all drug and/or exercise intervention studies). The experimental questions addressed in this study were *a priori* driven; however, a subset of participants' resting arterial blood gas variables have been reported elsewhere in a separate report (at sea level only) on the influence of ACZ on the pulmonary vascular pressure response to acute hypoxia and blood flow through intrapulmonary arteriovenous anastomoses (Tremblay *et al.*, 2015).

Ascent to High-Altitude

All variables and measurements were obtained at the University of British Columbia Okanagan Campus in Kelowna, BC, Canada (SL: 344 m, barometric pressure (Pb) 732 ± 16 mmHg) and following 14 to 20 days at the Ev-K2-CNR Pyramid Laboratory, Khumbu Valley, Nepal (HA: 5,050 m, Pb = 413 ± 4 mmHg). Participants spent 7 days in Kathmandu (1,338 m) acclimatizing before flying to Lukla (2,860 m) to begin the trek to 5,050 m over 6-8 days (rest days: Namche Bazaar, 3,440 m; Pengboche, 3,995 m; Pheriche, 4,371 m). Additionally, during the first 6-7 days of ascent to 5,050 m, participants were given low-dose acetazolamide (125 mg, oral) twice a day as an acute mountain sickness prophylactic (Basnyat *et al.*, 2006; Ritchie *et al.*, 2012). Treatment of acetazolamide was discontinued on day 8 of the trek at 4,371 m to allow sufficient time (e.g., >24 hours) for the drug to clear participants' system before the control trial at 5,050 m (Ritschel *et al.*, 1998; Richalet *et al.*, 2005). This approach was utilized to provide a safe ascent of the experimental volunteers at 5,050 m.

Protocol 1

At SL and following 14 to 20 days at HA participants first completed a control visit including a standardized intra-cranial cerebrovascular CO₂ reactivity (CVR) test including stepwise iso-oxic alterations in PaCO₂ (hypo- and hypercapnia) in the following order: -10, -5, +0, +5, +10, +15 mmHg PaCO₂ via dynamic end-tidal forcing. The alterations in PaCO₂ were calculated from the resting eupneic breathing end-tidal values obtained prior to each of the three experimental trials

at each altitude. Participants were unable to tolerate +15 mmHg PaCO₂ at 5,050 m; therefore, the hypercapnic CVR range was completed up to +10 mmHg PaCO₂ at HA. Each stage of the cerebrovascular CO₂ reactivity protocol lasted approximately 3 minutes to allow a steady-state responsiveness to be achieved (Carr *et al.*, unpublished). All cardiorespiratory, cerebrovascular, and arterial blood gas variables presented were measured within the last minute of each stage, representative of a steady-state.

Protocol 2 & 3

Following the control visit, participants were prescribed an oral dose of ACZ (250 mg) every 8 hours for 2 days before their next visit. The last dose of ACZ was taken 1 hour before experimentation. The cerebrovascular CO₂ reactivity protocol was then repeated twice (separated by at least 30 minutes) without intravenous NaHCO₃⁻ (ACZ) and with intravenous NaHCO₃⁻ (ACZ+HCO₃⁻). To allow for experimental alteration of arterial pH from a setting of relative metabolic acidosis caused by ACZ, the 8.4% intravenous NaHCO₃⁻ solution (Hospira, Montreal, Quebec, Canada) was delivered over a 15-minute infusion to acutely restore arterial pH to resting levels.

Arterial Blood Sampling

At SL, arterial blood samples (approx. 1.0 mL) were collected from the radial artery under local anesthesia (Lidocaine, 1.0%) using a 23-gauge needle and self-filling pre-heparinized syringe (SafePICO syringes, Radiometer, Copenhagen, Denmark). At HA, a radial artery catheter (20-gauge; Arrow, Markham, ON, Canada) was placed under local anesthesia (Lidocaine, 1.0%) and ultrasound guidance. The radial artery catheter was attached to an in-line waste-less blood sampling system (Edwards Lifesciences, TruWave VAMP, CA, USA) for repeated measurements. All blood gas samples were analyzed immediately using a calibrated blood gas analyzer (ABL90 FLEX, Radiometer). This analysis included measurements of the partial pressures of arterial carbon dioxide (PaCO₂) and oxygen (PaO₂), arterial oxygen saturation (SaO₂), bicarbonate ion concentration ([HCO₃⁻]), hydrogen ion concentration ([H⁺]), hemoglobin concentration ([Hb]), hematocrit (HCT) and arterial pH. All samples were heated/corrected to an assumed resting body temperature of 37.0°C.

ACID-BASE BALANCE AND CEREBRAL BLOOD FLOW AT HIGH-ALTITUDE

Blood gas analyzers do not typically have the capacity to directly measure ($[\text{HCO}_3^-]$); instead, it is calculated from measured PaCO_2 and pH, using the Henderson-Hasselbalch equation (Hasselbalch, 1916). The pKa (i.e., -log of the acid dissociation constant) at 37.0°C of 6.1 (Cullen *et al.*, 1925) and the solubility factor for dissolved CO_2 plus carbonic acid (H_2CO_3) at 37.0°C in plasma of 0.0314 mmol·l⁻¹ per mmHg PaCO_2 were used:

$$\text{pH} = 6.1 + \log [\text{HCO}_3^-] / (0.0314 \times \text{PaCO}_2)$$

At SL, arterial blood samples were obtained from the radial artery prior to each cerebrovascular CO_2 reactivity trial (e.g., control, ACZ, ACZ+ HCO_3^-) in a subgroup of participants (n=7) and again in five participants following the ACZ+ HCO_3^- protocol to confirm that arterial pH and $[\text{HCO}_3^-]$ were maintained for the duration of the experimental protocol. At HA, arterial blood samples were obtained in all 10 participants at rest prior to and during the cerebrovascular CO_2 reactivity protocols for the control and ACZ trials; the ACZ+ HCO_3^- trial was conducted on the next day at HA and arterial blood samples were obtained in a subgroup of participants (n=5).

At both SL and HA the deficit in $[\text{HCO}_3^-]$ was calculated from resting arterial $[\text{HCO}_3^-]$ taken with and without ACZ and using body mass to calculate the required dosage of NaHCO_3^- with the below equations (Kollef & Isakow, 2012).

$$\text{Apparent volume of distribution} = \text{total body weight (kg)} \times (0.4 + (2.4 / \text{ACZ } [\text{HCO}_3^-]))$$

$$\text{Target change in } [\text{HCO}_3^-] = \text{resting } [\text{HCO}_3^-] - \text{ACZ } [\text{HCO}_3^-]$$

$$\text{mEq of NaHCO}_3^- = \text{Apparent volume of distribution} \times \text{target change in } [\text{HCO}_3^-] \times 0.5$$

Arterial blood samples were obtained following NaHCO_3^- infusion to confirm sufficient normalization to control values. In the event that $[\text{HCO}_3^-]$ was not completely restored to resting levels additional NaHCO_3^- was administered and arterial $[\text{HCO}_3^-]$ levels were reassessed before experimentation to confirm adequate restoration. The order of experiments was not randomized because of the lasting effects of ACZ and NaHCO_3^- .

Cardiorespiratory

Breath-by-breath CO_2 and O_2 were sampled at the mouth and recorded using a gas analyzer calibrated prior to each experimental session (ML206, ADInstruments, CO, USA). The partial pressures of end-tidal CO_2 and O_2 (i.e., P_{ETCO_2} and P_{ETO_2} , respectively) were calculated in LabChart (ADInstruments) using peak detection analysis with correction for daily barometric pressure at BTPS. Both P_{ETCO_2} and P_{ETO_2} were controlled using a custom-designed dynamic end-tidal forcing system to effectively regulate end-tidal gases across wide ranges of P_{ETCO_2} and P_{ETO_2} independent of ventilation (\dot{V}_E); this device has previously been described in detail elsewhere (Tymko *et al.*, 2015; 2016). Notably, this method of arterial blood gas alteration attenuates the end-tidal-to-arterial PCO_2 gradient, precludes any influence of \dot{V}_E on cerebrovascular CO_2 reactivity (Howe *et al.*, 2020), and therefore provides an accurate stimulus-response relationship (Fisher, 2016; Fisher *et al.*, 2018). Respiratory flow, tidal volume (V_T), and respiratory frequency (f_R) were measured by a pneumotachograph (HR 800 L, Hans Rudolph, Shawnee, KS, USA). Instantaneous minute ventilation (\dot{V}_E in liters per minute) was determined as the product of breath-by-breath inspired volume (V_T ; calculated from the integral of the flow signal) and respiratory frequency (f_R , in breaths per minutes; calculated by $60/\text{period of the flow signal}$).

Cardiovascular

At HA, beat-by-beat arterial blood pressure was acquired via the radial artery pressure transducer positioned at the height of the right atrium (Edwards Lifesciences, TruWave VAMP, CA, USA). At SL, continuous non-invasive blood pressure was acquired using finger photoplethysmography (Finometer PRO, Finapres Medical Systems, Amsterdam, Netherlands) and was calibrated prior to data collection using the return-to-flow function and normalized to manual brachial artery blood pressure measurements. The arterial and finger photoplethysmography blood pressure waveforms were averaged to calculate MAP at each altitude, respectively. Heart rate was continuously measured using a lead-II electrocardiogram (ECG; ML132 BioAmp, ADInstruments, CO, USA). Peripheral oxygen saturation (SpO_2) was measured continuously by pulse oximetry (ML320/F; ADInstruments, CO, USA).

Cerebrovascular

At rest, extra-cranial blood velocity and vessel diameter of the left internal carotid artery (ICA) and right vertebral artery (VA) were measured using a 10-MHz multifrequency linear array Duplex ultrasound (Terason t3000; Teratech, Burlington, MA, USA). Pulse-wave mode was used to measure peak blood velocity and arterial diameter was instantaneously measured using B-mode imaging. The ICA blood velocity and vessel diameter were measured ≥ 1.5 cm from the carotid bifurcation to avoid any turbulent or retrograde flow patterns, while VA blood velocity and diameter were measured between C4-C5 or C5-C6. The vessel location was decided on an individual basis to allow for reliable image acquisition, with the same location and consistent insonation angle (60°) repeated within participants and between trials. Our between-day coefficients of variation for Q_{ICA} and Q_{VA} are 5% and 11%, respectively (Willie *et al.*, 2012). Intra-cranial cerebral blood velocity (CBV) was assessed at rest and during CO₂ reactivity via transcranial Doppler (TCD) ultrasound (Spencer Technologies, Seattle, WA, USA), as an index of CBF, in the left middle cerebral artery (MCA) and right posterior cerebral artery (PCA). The 2-MHz TCD probes were attached to a specialized headband (model M600 bilateral head frame, Spencer Technologies), and each vessel was insonated through the trans-temporal window, using previously described location and standardization techniques (Willie *et al.*, 2011). Our between-day coefficients of variation for MCA_v and PCA_v are 3% and 2%, respectively (Smith *et al.*, 2012).

Data Analyses

Cardiovascular and respiratory measures were sampled continuously at 1000 Hz using an analogue-to-digital converter (Powerlab/16SP ML795; ADInstruments, Colorado Springs, CO, USA) and data were interfaced with LabChart (Version 7.1) and analyzed offline. Cardiovascular and respiratory variables presented are 1-minute averages during steady-state conditions after ≥ 2 minutes at each stage of the CO₂ reactivity protocol. The Q_{ICA} and Q_{VA} recordings were at least 1-minute for each measurement (Thomas *et al.*, 2015). Duplex ultrasound recordings were screen captured and saved for offline analysis using custom edge-detection and wall tracking software (BloodFlow Analysis, version 5.1). This analysis method utilizes integration of diameter and velocity traces to calculate mean beat-to-beat flow at 30 Hz independent of observer bias (Woodman *et al.*, 2001).

Blood flow was calculated as:

$$Q \text{ (mL}\cdot\text{min}^{-1}\text{)} = \text{peak envelope blood velocity} / 2 \times (\pi(0.5 \times \text{diameter})^2) \times 60.$$

Global cerebral blood flow (gCBF) was calculated as:

$$gCBF \text{ (mL}\cdot\text{min}^{-1}\text{)} = 2 \times (Q_{ICA} + Q_{VA})$$

Arterial oxygen content (CaO₂) was calculated as:

$$CaO_2 \text{ (mL}\cdot\text{dL}^{-1}\text{)} = [\text{Hb}] \times 1.34 \times [\text{SaO}_2 \text{ (\%)} / 100] + 0.003 \times PaO_2$$

Where 1.34 is the O₂ binding capacity of hemoglobin and 0.003 is the solubility of O₂ dissolved in blood (Lumb, 2016; West & Luks, 2020).

Cerebral oxygen delivery (CDO₂) was calculated as:

$$CDO_2 \text{ (mL}\cdot\text{min}^{-1}\text{)} = gCBF \times CaO_2$$

$$MCA \text{ or PCA } DO_2 \text{ (au)} = MCA_v \text{ or PCA}_v \times CaO_2$$

Cerebrovascular conductance (CVC) was calculated as:

$$CVC \text{ (mL}\cdot\text{min}^{-1}\cdot\text{mmHg}^{-1}\text{)} = gCBF, Q_{ICA}, Q_{VA}, MCA_v, \text{ or PCA}_v / MAP$$

Statistical Analyses

All data are presented as mean \pm SD. Statistical analyses were performed using SPSS software (IBM statistics, Version 23.0) and statistical significance was set at $P \leq 0.05$. Comparisons were made between SL and HA at rest between trials (control, ACZ, ACZ+HCO₃⁻), and between PaCO₂ stages within elevation. A linear mixed-model analysis with compound symmetry covariance structure with fixed effects of trial (control, ACZ, ACZ+HCO₃⁻) and altitude (SL vs. HA) was used to compare arterial blood gas, cardiorespiratory, and cerebrovascular variables at rest. Resting MAP, PaCO₂, pH, [HCO₃⁻], and CaO₂ were added as covariates alongside trial and altitude as fixed effects and subjects as a random effect for resting gCBF. The selected variables were chosen as they are considered important regulators of CBF in humans (Willie *et al.*, 2014) and they each improved the model fit (-2 Log Likelihood), indicating their acceptability in the model. A Bonferroni correction was applied for multiple comparisons when significant

interactions were detected. A linear mixed-model analysis with fixed effects of trial (control, ACZ, ACZ+HCO₃⁻) and stage (PaCO₂ level) was used during the cerebrovascular CO₂ reactivity protocol for separate SL and HA comparisons. Separate hypo- and hypercapnic CVR was analyzed using linear regression to calculate the individual slope response between cerebrovascular parameters and P_{ET}CO₂. A one-tailed, paired Student's t-test was used to compare the individual x-intercept values for the absolute PaCO₂ versus pH and MCA_v versus pH cerebrovascular CO₂ reactivity slopes between each experimental trial at HA.

RESULTS

Arterial blood gases

Between altitudes within trials at rest: As expected, HA resulted in arterial hypoxemia (PaO₂: Δ -53 \pm 6 mmHg and SaO₂: Δ -13.4 \pm 1.3 %, altitude effects: P < 0.001 and P < 0.001, respectively; **Table 1**) and respiratory alkalosis (PaCO₂: Δ -14.7 \pm 2.3 mmHg and pH: Δ +0.03 \pm 0.04, altitude effects: P < 0.001 and P = 0.002, respectively; **Table 1**) with partial metabolic compensation ([HCO₃⁻]: Δ -7.6 \pm 1.4 mEq·l⁻¹, within trials all P < 0.001; **Table 1**). Overall, CaO₂ was lower at HA versus SL during control and ACZ trials (P < 0.001 and P < 0.001, respectively; **Table 1**) with no change between altitudes during the ACZ+HCO₃⁻ trial (P = 0.433; **Table 1**).

Between trials across altitudes at rest: Across altitudes, arterial pH was lower following ACZ versus control (Δ -0.07 \pm 0.04, trial effect: P < 0.001; **Table 1**) and ACZ+HCO₃⁻ (Δ -0.06 \pm 0.04, trial effect: P < 0.001; **Table 1**); that is, ACZ+HCO₃⁻ effectively restored arterial pH to control values at both SL and HA. Following ACZ, arterial [HCO₃⁻] was lower at SL (Δ -6.3 \pm 2.0 mEq·l⁻¹, P < 0.001; **Table 1**) and HA (Δ -3.9 \pm 2.1 mEq·l⁻¹, P < 0.001; **Table 1**); as such, NaHCO₃⁻ infusion effectively normalized arterial [HCO₃⁻] to control values at each altitude (P = 0.279 and P = 0.060, respectively; **Table 1**). Following ACZ at SL and HA, PaCO₂ was lower (Δ -3.4 \pm 2.3 mmHg, trial effect: P < 0.001; **Table 1**) and PaO₂ was higher (Δ +6.3 \pm 6.5 mmHg, trial effect: P = 0.003; **Table 1**) with no change between control and ACZ+HCO₃⁻ trials (trial effect: P = 0.053 and P = 0.458, respectively; **Table 1**). At SL, CaO₂ was higher following ACZ versus control (Δ +1.2 \pm 1.0 mL·dL⁻¹, P < 0.001; **Table 1**) and ACZ+HCO₃⁻ (Δ +1.2 \pm 1.0

mL·dL⁻¹, $P = 0.001$; **Table 1**) trials. At HA, CaO₂ was also higher following ACZ ($\Delta +1.8 \pm 1.1$ mL·dL⁻¹, $P < 0.001$; **Table 1**) and ACZ+HCO₃⁻ ($\Delta +1.7 \pm 1.4$ mL·dL⁻¹, $P < 0.001$; **Table 1**) versus the control trial.

Cardiorespiratory

There was no interaction between the resting \dot{V}_E , HR, and MAP responses between control, ACZ, and ACZ+HCO₃⁻ trials and SL versus HA (all $P > 0.05$; **Table 2**). Throughout the CO₂ reactivity tests, there was no interaction between the \dot{V}_E , HR, and MAP responses between trials at either altitude (all $P > 0.05$). Across altitudes, MAP was lower at rest and throughout the CO₂ reactivity tests during the ACZ trial compared to control and ACZ+HCO₃⁻ trials (trial effects: all $P < 0.05$; **Table 2**).

Cerebrovascular

There was no interaction between the resting CDO₂, gCBF, and gCBF_{CVC} responses between control, ACZ, and ACZ+HCO₃⁻ trials and SL versus HA (all $P > 0.05$; **Table 2**). Resting CDO₂, gCBF, and gCBF_{CVC} were all higher at HA versus SL (altitude effects: all $P < 0.05$; **Table 2**). Further, covariate analysis revealed no significant influence of resting PaCO₂, pH, or [HCO₃⁻] on resting CDO₂, gCBF, and gCBF_{CVC} responses between trials and altitudes (all $P > 0.05$). As such, there was no correlation between the absolute resting PaCO₂, [H⁺], or pH and the respective gCBF within trials at each altitude (all $P > 0.05$).

Regulation of resting cerebral blood flow by arterial PCO₂, pH, and H⁺: **Figure 1** provides context for the intra-individual variability in resting acid-base balance (i.e., metabolic/respiratory compensation) and respective CBF regulation within the ACZ and ACZ+HCO₃⁻ experimental trials. As ACZ provokes reductions in both arterial pH and PaCO₂ (**Table 1**) – via metabolic acidosis and elevated respiration – it is important to consider the directional alterations in gCBF responses with these respective competing changes in PaCO₂ and [H⁺]/pH between trials at SL and HA. Overall, an unchanged gCBF response corresponded with a higher arterial [H⁺] (i.e., lower pH) as well as a reduction in PaCO₂ following ACZ; that is, respiratory compensation (i.e., Δ PaCO₂), rather than the prevailing arterial [H⁺]/pH, is sufficient to offset any changes in gCBF with ACZ and ACZ+HCO₃⁻ acid-base alterations at SL and HA.

High-altitude MCAv CO₂ reactivity regulation: Throughout the CO₂ reactivity tests at HA, arterial pH was lower during the ACZ trial than control ($\Delta -0.08 \pm 0.01$, trial effect: $P < 0.001$; **Figure 2**) and ACZ+HCO₃⁻ ($\Delta -0.03 \pm 0.02$, trial effect: $P < 0.001$; **Figure 2**). The arterial pH was lower during the ACZ+HCO₃⁻ versus control trial CO₂ reactivity test ($\Delta -0.05 \pm 0.02$, trial effect: $P < 0.001$; **Figure 2**) even though arterial pH was not different at rest between ACZ+HCO₃⁻ and control trials ($P = 0.060$). Across PaCO₂ stages, CaO₂ was higher than the control trial with both ACZ ($\Delta +1.4 \pm 0.4 \text{ mL}\cdot\text{dL}^{-1}$, trial effect: $P < 0.001$) and ACZ+HCO₃⁻ ($\Delta +1.7 \pm 0.5 \text{ mL}\cdot\text{dL}^{-1}$, trial effect: $P < 0.001$); as such, MCA DO₂ was not different between trials (trial effect: $P = 0.622$). Across the full range of PaCO₂ alterations, there was no difference between the sensitivity (i.e., slope) of the absolute MCAv response to changes in PaCO₂, [H⁺], or pH ($P = 0.156$, $P = 0.238$, and $P = 0.073$, respectively) across trials at HA (**Figure 2 A & B**). Additionally, absolute MCAv was not different at each stage of PaCO₂ between trials at HA ($P = 0.913$).

Hypocapnic versus hypercapnic reactivity: Within altitudes at SL and HA, there was no difference between either the absolute MCAv or PCAv (each covariate adjusted by MAP; all $P < 0.001$) versus P_{ET}CO₂/PaCO₂ responses, respectively across the full range of CO₂ reactivity (i.e., inclusive of hypo- and hypercapnia) between control, ACZ, and ACZ+HCO₃⁻ (all $P > 0.05$; **Figure 3A & 3B**). Across trials, the separate hypocapnic and hypercapnic relative CVR slopes were higher at HA versus SL for MCAv, PCAv, MCA_{CVC}, and PCA_{CVC} (altitude effects: all $P < 0.05$; **Table 3 & Figure 3C**). Across altitudes, absolute and relative MCAv hypercapnic CVR were both higher during the control trial than ACZ and ACZ+HCO₃⁻ with no influence of altitude *per se* (trial effects: $P = 0.004$ and $P = 0.005$; **Tables 3-4 & Figure 3D**). At HA, relative PCA_{CVC} hypocapnic CVR was lower during the ACZ+HCO₃⁻ trial than control ($-15 \pm 24\%$, $P = 0.028$) and ACZ ($-21 \pm 18\%$, $P = 0.003$). At SL, the absolute hypocapnic CVR was higher during the ACZ+HCO₃⁻ trial than control for MCAv ($+0.8 \pm 0.7 \text{ cm}\cdot\text{s}^{-1}$ per mmHg, $P = 0.003$), MCA_{CVC} ($+0.01 \pm 0.01 \text{ cm}\cdot\text{s}^{-1}$ per mmHg, $P = 0.004$), and PCA_{CVC} ($+0.01 \pm 0.00 \text{ cm}\cdot\text{s}^{-1}$ per mmHg, $P = 0.021$) (**Table 4**). These between trial differences in the absolute hypocapnic CVR responses to ACZ+HCO₃⁻ were not apparent at HA.

DISCUSSION

The results of this study indicate that in the context of acute and chronic changes in arterial pH the CBF response is consistent with changes in PaCO_2 rather than the prevailing arterial $[\text{H}^+]/\text{pH}$ *per se*. These data support the view that the buffering capacity of extracellular rather than intravascular arterial $[\text{H}^+]/\text{pH}$ gradients regulate CBF as cerebrovascular CO_2 reactivity was consistently higher following partial acclimatization to high-altitude versus sea level irrespective of experimentally controlled metabolic acidosis/alkalosis. This finding is supported by: 1) resting CBF and cerebrovascular CO_2 reactivity were unchanged between trials within each altitude even though arterial pH and $[\text{HCO}_3^-]$ (i.e., buffering capacity) were effectively altered; and 2) intra-individual responses at rest indicate reductions in PaCO_2 (via respiratory compensation) are sufficient to regulate $g\text{CBF}$ with metabolic acidosis rather than the countervailing changes in arterial $[\text{H}^+]/\text{pH}$. Taken together, within the experimental constraints of this study, these findings indicate that CO_2 -mediated changes in cerebrovascular regulation rather than *arterial* $[\text{H}^+]/\text{pH}$ is integral in the regulation of CBF in humans following acclimatization to high-altitude.

Cerebrovascular regulation following acute and chronic alterations in acid base balance: Resting CBF was unaltered between trials within each altitude even though arterial pH and $[\text{HCO}_3^-]$ (i.e., buffering capacity) were effectively reduced and restored with ACZ and ACZ+ HCO_3^- trials, respectively (**Table 1**). These results are inconsistent with previous reports at HA of approximately 25% *increases* in resting CBF following 2 hours of a large oral ACZ ingestion (1.5 g; 3,475 m) (Jensen *et al.*, 1990) or rapid 60-s intravenous infusion (10 mg/kg; 5,050 m) (Fan *et al.*, 2012). It is noteworthy, however, that these studies were performed acutely with a higher relative ACZ dose than the current experiment (2 days; 250 mg per 8 hours) and such doses/intravenous approaches are not ecologically valid at HA (Low *et al.*, 2012; Bärtsch & Swenson, 2013). At SL, acute intravenous ACZ infusion rapidly elevates CBF (Ehrenreich *et al.*, 1961; Hauge *et al.*, 1983; Lassen *et al.*, 1987; Jensen *et al.*, 1990; Fan *et al.*, 2012) without altering cerebral metabolism (Posner & Plum, 1960; Vorstrup *et al.*, 1984); importantly, such acute intravenous protocols do not alter PaCO_2 whereas the expected hyperventilatory response was observed in the present study following 2 days oral ACZ (e.g., Δ -5 mmHg PaCO_2 ; **Table 1**). Further, reports indicate ACZ infusion attenuates the regulatory rise in CSF $[\text{HCO}_3^-]$ in

response to increases in PaCO_2 (Wichser & Kazemi, 1975; Kazemi *et al.*, 1976; Shibata *et al.*, 1976; Kazemi & Choma, 1977); therefore, *intravenous* ACZ may indeed exacerbate reductions in buffering capacity, necessitating an increase in CBF to maintain extravascular pH (Skinhoj, 1966; Severinghaus & Lassen, 1967; Lassen, 1968; Fencel *et al.*, 1969).

Well-established *in vivo* pre-clinical studies show that changes in PaCO_2 rather than arterial pH *per se* mediate alterations in CBF by stabilizing perivascular pH (Betz & Heuser, 1967; Wahl *et al.*, 1970; Betz *et al.*, 1973; Kontos *et al.*, 1977b; 1977a). As such, a rightward shift in the PaCO_2 -pH relationship at altitude and resultant reduction in buffering capacity (via lower $[\text{HCO}_3^-]$) would also result in a rightward shift in the CBF-pH relationship. This view is consistent with recent results from Caldwell and colleagues (2021) that show a rightward x-intercept shift in both the PaCO_2 -pH and CBF-pH responses following acute metabolic alkalosis via intravenous NaHCO_3^- at SL. Relatedly, between trials at HA, we observed *leftward* shifts in both the PaCO_2 -pH and CBF-pH relationships with experimentally *reduced* arterial pH (e.g., ACZ; **Figure 2A & 2C**). These data indicate that changes in the x-intercept of CBF versus pH were consistent with the altered relationship between PaCO_2 and pH at HA; i.e., the sensitivity of CBF to PaCO_2 *per se* was unchanged between trials at HA. At least at SL, previous studies report that metabolic acidosis has an equivalent or additive influence on the hypoxic ventilatory response (Forster & Klausen, 1973; Swenson & Hughes, 1993); however, the absolute change in PaCO_2 with ACZ was approximately 60% less at HA than at SL (**Table 1**). As discussed next, the leftward shift in the $\text{CBV-P}_{\text{ETCO}_2}$ response with ACZ at SL can likely be attributed to the larger absolute change in PaCO_2 with ACZ at SL (**Figure 3A**).

Cerebrovascular regulation is not exclusively regulated by arterial pH: These data support recent pre-clinical work which substantiates that CO_2 signalling – via astrocytic $\text{CO}_2/\text{HCO}_3^-$ transport – mediates CBF regulation (e.g., neurovascular coupling) independently of experimentally altered arterial/extracellular pH (Hosford *et al.*, 2021; *preprint*). Additionally, these results are consistent with evidence that PCO_2 -mediated release of ATP (via CO_2 -sensitive connexin-26 proteins) independent of extracellular acidosis and Ca^{2+} is integral to the ventilatory response to CO_2 (Huckstepp *et al.*, 2010; Cummins *et al.*, 2020); however, whether this CO_2 signalling is involved with CBF regulation requires investigation. The ACZ-induced reductions in arterial pH would theoretically increase gCBF if metabolic acidosis is considered exclusively

(Fencel *et al.*, 1969). Rather, gCBF was statistically unaltered between experimental trials within each altitude, indicating that respiratory compensation (i.e., reductions in PaCO₂) was sufficient to offset any elevations in gCBF expectedly induced by ACZ-mediated metabolic acidosis. In support of this finding, the intra-individual responses indicate that the reductions in PaCO₂ are consistent with the directional alterations in gCBF with ACZ and ACZ+HCO₃⁻ trials (**Figure 1**). Following ACZ at SL, resting PaCO₂ was reduced by approximately 5 mmHg (**Table 1**); taken together with the well-established hypocapnic CVR of approximately 3-4% per mmHg PaCO₂ (Kety & Schmidt, 1948; Ramsay *et al.*, 1993; Ito *et al.*, 2000; 2003; Willie *et al.*, 2012; Coverdale *et al.*, 2014; reviewed in: Hoiland *et al.*, 2019), these data indicate that the extent of respiratory compensation to ACZ is apparently exaggerated with respect to the unaltered gCBF. In support of this view, previous reports show a progressive 30% reduction in alveolar PCO₂ following 10 days of oral ACZ (500 mg twice daily); alongside this respiratory compensation, total CBF (via intravenous xenon¹³³ technique) was restored to control values within 2 days of ACZ treatment and throughout the following 15 days indicating a countervailing influence of acid-base balance on cerebrovascular regulation (Lassen *et al.*, 1987; Friberg *et al.*, 1990).

The relationship between arterial PCO₂ and H⁺/pH predicates cerebrovascular CO₂ reactivity at high-altitude: The present results are consistent with other studies that have reported higher cerebrovascular CO₂ reactivity with initial ascent and partial acclimatization to HA (Fan *et al.*, 2010; 2012; 2014; Flück *et al.*, 2015). Within each altitude, there were selective alterations in absolute and relative hypocapnic CVR during the ACZ+HCO₃⁻ trial (**Tables 3-4**); such findings are perhaps attributable to relative increases in buffering capacity via exogenously elevated arterial [HCO₃⁻] (Siesjö, 1972) and/or direct effects of extracellular [HCO₃⁻] on cerebrovascular tone via changes in vascular smooth muscle cell contractility and Ca²⁺ sensitivity (Boedtkjer *et al.*, 2016; Boedtkjer, 2018). As the NaHCO₃⁻ infusion acutely restored pH – rather than promoting further metabolic alkalosis – it is likely that these effects are due to the exogenous increases in arterial [HCO₃⁻] rather than pH *per se*. It is noteworthy that the absolute MCAv was not different at each stage of PaCO₂ between experimental trials at HA (**Figure 2B**). Pioneering work by Severinghaus and colleagues (1963) revealed tight regulation of CSF pH with chronic hypocapnia and arterial alkalosis following 8 days of acclimatization to 3,800 m – although the capacity of CSF [HCO₃⁻] active transport is reportedly controversial, these data illustrate the

importance of interstitial/extracellular pH regulation (Severinghaus *et al.*, 1963; Severinghaus, 1965; Mitchell *et al.*, 1965; Pappenheimer 1970, 1970; Hasan & Kazemi, 1976; Kazemi & Choma, 1977; Bledsoe *et al.*, 1981). Overall, the hyperventilatory-induced reductions in PaCO₂ (i.e., respiratory alkalosis) correspond with the slow exchange of CSF [HCO₃⁻] to normalize CSF pH and CBF with progressive acclimatization, further substantiating that arterial pH *per se* does not dictate CBF regulation. We interpret the unaltered CBF-PaCO₂ response between trials at HA to indicate that CBF is acutely regulated by PaCO₂ within the context of acute and chronic alterations in arterial pH following partial acclimatization to 5,050 m.

Experimental considerations: With this experimental protocol we were restricted by the lasting effects of ACZ and NaHCO₃⁻ on acid-base balance; therefore, the order of trials were not randomized within altitudes. Without an appropriate time-control, changes in CaO₂ may have occurred due to acclimatization to HA throughout the testing sessions that lasted two days following 14-20 days at 5,050 m; however, this is unlikely as we observed a related increase in CaO₂ with ACZ at SL. It is noteworthy that ACZ attenuated MAP at both altitudes; e.g., MAP was reduced by approximately 12% at HA (i.e., $\Delta -13 \pm 5$ mmHg; **Table 2**), likely indicating a direct vasodilatory influence of ACZ on the systemic circulation (Parati *et al.*, 2013; Eskandari *et al.*, 2018) via opening of Ca²⁺-activated K⁺ channels (Pickkers *et al.*, 2001). Notwithstanding, covariate analysis revealed no influence of resting MAP on gCBF within each trial and the resting gCBF_{CVC} response was unaffected by ACZ at both altitudes (**Table 2**). Previous reports indicate that cerebral oxidative metabolism is higher at rest following 4-6 days at 5,050 m (Smith *et al.*, 2014), unaltered following 5 weeks at 5,260 m (Møller *et al.*, 2002), and likely varies with acute alterations in PaCO₂ (Willie *et al.*, 2015). As such, future investigations on the relationship between cerebrovascular acid-base regulation and metabolism at high-altitude are merited. It is unknown whether ACZ may differentially affect cerebral oxidative metabolism at high-altitude.

Technical considerations: A strength of the current study was the use of regional volumetric Q_{ICA} and Q_{VA} to calculate gCBF at rest; however, such an approach would be preferable to MCA_v/PCA_v estimates of CBF throughout the cerebrovascular CO₂ reactivity tests. Duplex ultrasound facilitates B-mode arterial diameter in the sagittal axis and pulse-wave blood velocity measurements to concurrently calculate volumetric blood flow (Thomas *et al.*, 2015).

Transcranial Doppler ultrasound only provides pulse-wave velocity without brightness (B-mode) imaging; therefore, this technique relies on the assumptions that arterial diameter and insonation angle are not changing (Ainslie & Hoiland, 2014). We appreciate that MCA_v systematically underestimates Duplex ultrasound and Fick-derived CBF reactivity to PaCO₂ at SL and 5,050 m (Willie *et al.*, 2015). As such, we attempted to standardize the response between trials at each altitude by utilizing an approach to calculate relative changes in CBV.

Additionally, continuous arterial blood gas sampling throughout the CO₂ reactivity tests at SL would have been advantageous to directly ascertain the changes in buffering capacity with respiratory acidosis/alkalosis. Bland-Altman analysis revealed that the resting P_{ET}CO₂-PaCO₂ gradients at SL and HA were 1.0 ± 3.1 and 3.7 ± 1.6 mmHg, respectively; consistent with previously reported values (Willie *et al.*, 2012; Tymko *et al.*, 2015). Importantly, the linearly related P_{ET}CO₂-PaCO₂ gradient (R^2 0.94, $P < 0.001$) throughout the cerebrovascular CO₂ reactivity tests at HA was consistent with the gradient observed at rest (e.g., 3.7 ± 1.6 vs. 3.7 ± 1.7 mmHg); therefore, the small (<3 mmHg) P_{ET}CO₂-PaCO₂ gradient at HA versus SL likely did not alter our findings. Relatedly, the validity of arterial pH and acid-base buffering as an index of CSF pH changes at HA deserves consideration. Reductions in CSF [HCO₃⁻] follow changes in arterial blood indicating that passive exchange of CO₂ across the blood-brain-barrier and resultant re-equilibrium of the reaction between CO₂ and HCO₃⁻ provokes changes in CSF [HCO₃⁻] and pH (Forster *et al.*, 1975; Weiskopf *et al.*, 1976). Dempsey and colleagues (1974) reported consistent CSF to arterial pH gradients (Δ -0.08 pH units) and closely matched [HCO₃⁻] between CSF and arterial samples at SL and following 3-4 weeks at 3,100 m. Additionally, they reported that the relative partial metabolic/respiratory compensation with acclimatization to HA was not different between arterial blood and CSF with respect to [H⁺]/pH and PCO₂ changes; as such, these data support the efficacy of arterial acid-base changes as an index of CSF regulation.

CONCLUSION

These findings reveal that in the context of acute and chronic changes in arterial pH – via partial acclimatization to high-altitude and experimentally controlled metabolic acidosis/alkalosis – including within trial acute alterations in PaCO₂ (i.e., respiratory acidosis/alkalosis), the CBF response is consistent with changes in PaCO₂ rather than the prevailing arterial [H⁺]/pH *per se*.

In support of this, we show that resting CBF and the cerebrovascular reactivity to PaCO₂ were unchanged between trials within each altitude even though arterial pH and [HCO₃⁻] (i.e., buffering capacity) were effectively altered. Taken together, these findings are consistent with previous studies indicating PaCO₂ and resultant passive diffusion of CO₂ across the vascular wall to alter perivascular pH, rather than arterial pH *per se*, acutely regulates CBF in humans.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Competing Interests

None to declare.

Author Contributions

PNA, SJEL, MS, and KRB conceived and designed the research. KJS, NL, RLH, CKW, SJEL, MS, KRB, DBM, and PNA acquired the data. HGC and RLH analyzed the data. HGC, RLH, and PNA interpreted the data. HGC drafted the manuscript. All authors revised the manuscript and provided intellectual feedback and agree to be accountable for all aspects of the work.

Funding

This study was funded by the Natural Sciences and Engineering Research Council of Canada (PNA) and a Canada Research Chair (PNA), as well as the Peninsula Health Care P/L (KRB). SJEL was funded by Lottery Health NZ and a University of Otago Research Grant.

Acknowledgements

This study was carried out within the framework of the Ev-K2-CNR Project in collaboration with the Nepal Academy of Science and Technology as foreseen by the Memorandum of Understanding between Nepal and Italy, and thanks to contributions from the Italian National Research Council. The authors are grateful to the other members of the UBC International Research Expedition to Mt Everest for invaluable help with logistical planning and completion of this research study.

TABLE CAPTIONS

Table 1. Arterial blood gas and acid-base parameters at rest during control, acetazolamide, and sodium bicarbonate infusion conditions at sea level (344 m) and high-altitude (5,050 m)

Abbreviations: Hydrogen concentration, $[H^+]$; bicarbonate concentration, $[HCO_3^-]$; arterial carbon dioxide tension, $PaCO_2$; arterial oxygen tension, PaO_2 ; arterial oxygen saturation, SaO_2 ; arterial oxygen content, CaO_2 ; hemoglobin concentration, $[Hb]$. Trial main effect pairwise comparisons: $^aP < 0.05$ versus control; $^bP < 0.05$ versus ACZ. Trial \times altitude interaction pairwise comparisons: $^{\#}P < 0.05$ versus control within altitude; $^{\$}P < 0.05$ versus ACZ within altitude; $^{+}P < 0.05$ versus control between altitudes; $^{\%}P < 0.05$ versus ACZ between altitudes; $^{\&}P < 0.05$ versus ACZ+ HCO_3^- between altitudes. Data are mean \pm SD. Sample sizes: $n=7$ for all three trials at sea level (SL), $n=10$ for the control and ACZ trials at high-altitude (HA), and $n=5$ for the ACZ+ HCO_3^- trial at HA.

Table 2. Cardiorespiratory and cerebrovascular parameters at rest during control, acetazolamide, and sodium bicarbonate infusion conditions at sea level (344 m) and high-altitude (5,050 m)

Abbreviations: Ventilation, \dot{V}_E ; tidal volume, V_T ; respiratory frequency, f_R ; breaths per minute, BPM; heart rate, HR; beats per minute, bpm; mean arterial pressure, MAP; cerebral oxygen delivery, CDO_2 ; global cerebral blood flow, $gCBF$; global cerebrovascular conductance, $gCBF_{CVC}$. Trial main effect pairwise comparisons: $^bP < 0.05$ versus ACZ. Trial \times altitude interaction pairwise comparisons: $^{\%}P < 0.05$ versus ACZ between altitudes. Data are mean \pm SD for $n=11$ at sea level (SL) and $n=10$ at high-altitude (HA).

Table 3. Relative cerebrovascular CO_2 reactivity during control, acetazolamide, and sodium bicarbonate infusion conditions at sea level (344 m) and high-altitude (5,050 m)

Abbreviations: Middle cerebral artery blood velocity, $MCAv$; Posterior cerebral artery blood velocity, $PCAv$; cerebrovascular conductance, CVC; hypocapnia, hypo-; hypercapnia, hyper-. Trial main effect pairwise comparisons: $^aP < 0.05$ versus control. Trial \times altitude interaction pairwise comparisons: $^{\#}P < 0.05$ versus control within altitude; $^{\$}P < 0.05$ versus ACZ within altitude; $^{+}P < 0.05$ versus control between altitudes; $^{\%}P < 0.05$ versus ACZ between altitudes; $^{\&}P < 0.05$ versus ACZ+ HCO_3^- between altitudes. Data are mean \pm SD. Sample sizes: SL control, $n=10$; SL ACZ, $n=11$; SL ACZ+ HCO_3^- , $n=11$; HA control, $n=10$; HA ACZ, $n=9$; HA ACZ+ HCO_3^- , $n=9$.

Table 4. Absolute cerebrovascular CO_2 reactivity during control, acetazolamide, and sodium bicarbonate infusion conditions at sea level (344 m) and high-altitude (5,050 m)

Abbreviations: Middle cerebral artery blood velocity, $MCAv$; Posterior cerebral artery blood velocity, $PCAv$; cerebrovascular conductance, CVC; hypocapnia, hypo-; hypercapnia, hyper-. Trial main effect pairwise comparisons: $^aP < 0.05$ versus control. Trial \times altitude interaction pairwise comparisons: $^{\#}P < 0.05$ versus control within altitude; $^{\$}P < 0.05$ versus ACZ within

altitude; $^+P < 0.05$ versus control between altitudes; $^*P < 0.05$ versus ACZ+HCO₃⁻ between altitudes. Data are mean \pm SD. Sample sizes: SL control, n=10; SL ACZ, n=11; SL ACZ+HCO₃⁻, n=11; HA control, n=10; HA ACZ, n=9; HA ACZ+HCO₃⁻, n=9.

FIGURE CAPTIONS

Figure 1. Global cerebral blood flow (gCBF) regulation at rest during acetazolamide (ACZ) and acetazolamide with bicarbonate (ACZ+HCO₃⁻) trials at sea level (**A** & **C**) and high-altitude (**B** & **D**). Each panel shows the intra-individual variability between the absolute change in arterial H⁺ (**A** & **B**) and PCO₂ (PaCO₂) (**C** & **D**) and the respective relative change in gCBF. The absolute change in H⁺ and PaCO₂, and the relative change in gCBF are compared to the control trial values, respectively. Overall, an unchanged gCBF response corresponded with a higher arterial [H⁺] (i.e., lower pH) as well as a reduction in PaCO₂ following ACZ; that is, respiratory compensation (i.e., Δ PaCO₂), rather than the prevailing arterial [H⁺]/pH, is sufficient to offset any changes in gCBF with ACZ and ACZ+HCO₃⁻ acid-base alterations at SL and HA. Data are individual values with group averages. Sample sizes: n=8 for SL both trials, n=8 for ACZ at HA, and n=5 for ACZ+HCO₃⁻ at HA.

Figure 2. Acid-base balance and cerebrovascular regulation throughout CO₂ reactivity tests during control, acetazolamide (ACZ) and acetazolamide with bicarbonate (ACZ+HCO₃⁻) trials at high-altitude. There was a significant leftward shift in the x-intercept in the absolute MCA_v versus pH response within the ACZ versus control trial (7.59 ± 0.04 vs. 7.71 ± 0.08 , $P = 0.002$); however, this was reversed with ACZ+HCO₃⁻ (7.65 ± 0.04 vs. 7.71 ± 0.08 , $P = 0.086$) (**A**). These leftward x-intercept shifts were consistent with the PaCO₂ versus pH response between trials (**C**); i.e., the altered relationship between PaCO₂-pH was reflected in a leftward shift in the MCA_v-pH response. It is noteworthy that the absolute MCA_v was not different at each stage of PaCO₂ between trials at HA (**B**). Throughout the CO₂ reactivity tests, CaO₂ was not significantly different between trials when indexed against arterial pH (**D**). Data are mean \pm SD for n=10 for control & ACZ and n=5 for ACZ+HCO₃⁻.

Figure 3. Cerebrovascular regulation throughout CO₂ reactivity tests during control, acetazolamide (ACZ) and acetazolamide with bicarbonate (ACZ+HCO₃⁻) trials at sea level (SL) and high-altitude (HA). At SL, the MCA_{CVC}-P_{ET}CO₂ response was leftward shifted with ACZ and ACZ+HCO₃⁻ and this was likely explained by the significant reduction in *resting* PaCO₂ within these trials (**A**). As the absolute change in resting PaCO₂ with ACZ and ACZ+HCO₃⁻ was less at HA, there was no difference between the MCA_{CVC}-PaCO₂ responses between trials (**B**). The MCA_v hypo- and hypercapnic CVR was consistently higher at HA compared to SL irrespective of trial (**C** & **D**). Across altitudes, MCA_v hypercapnic CVR was higher during the control trial than ACZ and ACZ+HCO₃⁻ with no influence of altitude *per se* (**D**). Data are mean \pm SD (**A** & **B**) and individual values with group averages (**C** & **D**). Sample sizes: (**A**) n=10 for control and n=11 for ACZ & ACZ+HCO₃⁻; (**B**) n=10 for control & ACZ and n=5 for ACZ+HCO₃⁻; (**C**) & (**D**) n=10 for SL control, n=11 for SL ACZ & ACZ+HCO₃⁻, n=10 for HA control, n=9 for HA ACZ & ACZ+HCO₃⁻.

References:

- Abeyssekara S, Zello GA, Lohmann KL, Alcorn J, Hamilton DL & Naylor JM (2012). Infusion of sodium bicarbonate in experimentally induced metabolic acidosis does not provoke cerebrospinal fluid (CSF) acidosis in calves. *Can J Vet Res* **76**, 16–22.
- Ainslie PN & Burgess KR (2008). Cardiorespiratory and cerebrovascular responses to hyperoxic and hypoxic rebreathing: Effects of acclimatization to high altitude. *Respiratory Physiology & Neurobiology* **161**, 201–209.
- Ainslie PN & Hoiland RL (2014). Transcranial Doppler ultrasound: Valid, invalid, or both? *Journal of Applied Physiology* **117**, 1081–1083.
- Ainslie PN, Ogoh S, Burgess K, Celi L, McGrattan K, Peebles K, Murrell C, Subedi P & Burgess KR (2008). Differential effects of acute hypoxia and high altitude on cerebral blood flow velocity and dynamic cerebral autoregulation: alterations with hyperoxia. *Journal of Applied Physiology* **104**, 490–498.
- Arieff AI, Kerian A, Massry SG & DeLima J (1976). Intracellular pH of brain: alterations in acute respiratory acidosis and alkalosis. *American Journal of Physiology-Legacy Content* **230**, 804–812.
- Basnyat B et al. (2006). Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. *High Alt Med Biol* **7**, 17–27.
- Bärtsch P & Swenson ER (2013). Clinical practice: Acute high-altitude illnesses. *N Engl J Med* **368**, 2294–2302.
- Bernthal T (1937). CHEMO-REFLEX CONTROL OF VASCULAR REACTIONS THROUGH THE CAROTID BODY. *American Journal of Physiology-Legacy Content* **121**, 1–20.
- Betz E & Heuser D (1967). Cerebral cortical blood flow during changes of acid-base equilibrium of the brain. *J Appl Physiol* **23**, 726–733.
- Betz E, Enzenrobb HG & Vlahov V (1973). Interaction of H⁺ and Ca⁺⁺ in the regulation of local pial vascular resistance. *Pflugers Arch* **343**, 79–88.
- Bledsoe SW, Eng DY & Hornbein TF (1981). Evidence of active regulation of cerebrospinal fluid acid-base balance. *J Appl Physiol Respir Environ Exerc Physiol* **51**, 369–375.
- Boedtkjer E (2018). Acid-base regulation and sensing: Accelerators and brakes in metabolic regulation of cerebrovascular tone. *J Cereb Blood Flow Metab* **38**, 588–602.
- Boedtkjer E, Hansen KB, Boedtkjer DM, Aalkjaer C & Boron WF (2016). Extracellular HCO₃⁻ is sensed by mouse cerebral arteries: Regulation of tone by receptor protein tyrosine phosphatase γ . *Journal of Cerebral Blood Flow & Metabolism* **36**, 965–980.

ACID-BASE BALANCE AND CEREBRAL BLOOD FLOW AT HIGH-ALTITUDE

- 748 Bradley RD & Semple SJ (1962). A comparison of certain acid—base characteristics of arterial
749 blood, jugular venous blood and cerebrospinal fluid in man, and the effect on them of some
750 acute and chronic acid—base disturbances. *J Physiol (Lond)* **160**, 381–391.
- 751 Caldwell HG, Howe CA, Chalifoux CJ, Hoiland RL, Carr JMJR, Brown CV, Patrician A,
752 Tremblay JC, Panerai RB, Robinson TG, Minhas JS & Ainslie PN (2021). Arterial carbon
753 dioxide and bicarbonate rather than pH regulate cerebral blood flow in the setting of acute
754 experimental metabolic alkalosis. *J Physiol (Lond)* JP280682.
- 755 Coverdale NS, Gati JS, Opalevych O, Perrotta A & Shoemaker JK (2014). Cerebral blood flow
756 velocity underestimates cerebral blood flow during modest hypercapnia and hypocapnia. *J*
757 *Appl Physiol* **117**, 1090–1096.
- 758 Crawford RD & Severinghaus JW (1978). CSF pH and ventilatory acclimatization to altitude. *J*
759 *Appl Physiol Respir Environ Exerc Physiol* **45**, 275–283.
- 760 Cullen GE, Keeler HR & Robinson HW (1925). The pK' of the Henderson-Hasselbalch equation
761 for hydrogen concentration of serum. *J Biol Chem* **66**, 301–322.
- 762 Cummins EP, Strowitzki MJ & Taylor CT (2020). Mechanisms and Consequences of Oxygen
763 and Carbon Dioxide Sensing in Mammals. *Physiological Reviews* **100**, 463–488.
- 764 Dempsey JA, Forster HV & DoPico GA (1974). Ventilatory acclimatization to moderate
765 hypoxemia in man. The role of spinal fluid (H⁺). *Journal of Clinical Investigation* **53**, 1091–
766 1100.
- 767 Dempsey JA, Forster HV, Chosy LW, Hanson PG & Reddan WG (1978). Regulation of CSF
768 [HCO₃⁻] during long-term hypoxic hypocapnia in man. *J Appl Physiol Respir Environ Exerc*
769 *Physiol* **44**, 175–182.
- 770 Ehrenreich DL, Burns RA, Alman RW & Fazekas JF (1961). Influence of acetazolamide on
771 cerebral blood flow. *Arch Neurol* **5**, 227–232.
- 772 Eskandari D, Zou D, Grote L, Hoff E & Hedner J (2018). Acetazolamide Reduces Blood
773 Pressure and Sleep-Disordered Breathing in Patients With Hypertension and Obstructive
774 Sleep Apnea: A Randomized Controlled Trial. *J Clin Sleep Med* **14**, 309–317.
- 775 Fan J-L, Burgess KR, Basnyat R, Thomas KN, Peebles KC, Lucas SJE, Lucas RAI, Donnelly J,
776 Cotter JD & Ainslie PN (2010). Influence of high altitude on cerebrovascular and ventilatory
777 responsiveness to CO₂. *J Physiol (Lond)* **588**, 539–549.
- 778 Fan J-L, Burgess KR, Thomas KN, Lucas SJE, Cotter JD, Kayser B, Peebles KC & Ainslie PN
779 (2012). Effects of acetazolamide on cerebrovascular function and breathing stability at 5050
780 m. *J Physiol (Lond)* **590**, 1213–1225.
- 781 Fan J-L, Subudhi AW, Duffin J, Lovering AT, Roach RC & Kayser B (2015). AltitudeOmics:
782 Resetting of Cerebrovascular CO₂ Reactivity Following Acclimatization to High Altitude.
783 *Frontiers in Physiology* **6**, 394.

ACID-BASE BALANCE AND CEREBRAL BLOOD FLOW AT HIGH-ALTITUDE

- 784 Fan J-L, Subudhi AW, Evero O, Bourdillon N, Kayser B, Lovering AT & Roach RC (2014).
785 AltitudeOmics: enhanced cerebrovascular reactivity and ventilatory response to CO₂ with
786 high-altitude acclimatization and reexposure. *J Appl Physiol* **116**, 911–918.
- 787 Fencel V & Rossing TH (1989). Acid-base disorders in critical care medicine. *Annu Rev Med* **40**,
788 17–29.
- 789 Fencel V, Miller TB & Pappenheimer JR (1966). Studies on the respiratory response to
790 disturbances of acid-base balance, with deductions concerning the ionic composition of
791 cerebral interstitial fluid. *American Journal of Physiology-Legacy Content* **210**, 459–472.
- 792 Fencel V, Vale JR & Broch JA (1969). Respiration and cerebral blood flow in metabolic acidosis
793 and alkalosis in humans. *J Appl Physiol* **27**, 67–76.
- 794 Fisher JA (2016). The CO₂ stimulus for cerebrovascular reactivity: Fixing inspired
795 concentrations vs. targeting end-tidal partial pressures. *J Cereb Blood Flow Metab* **36**, 1004–
796 1011.
- 797 Fisher JA, Venkatraghavan L & Mikulis DJ (2018). Magnetic Resonance Imaging–Based
798 Cerebrovascular Reactivity and Hemodynamic Reserve. *Stroke* **49**, 2011–2018.
- 799 Flück D, Siebenmann C, Keiser S, Cathomen A & Lundby C (2015). Cerebrovascular Reactivity
800 is Increased with Acclimatization to 3,454 m Altitude. *Journal of Cerebral Blood Flow &*
801 *Metabolism* **35**, 1323–1330.
- 802 Forster HV & Klausen K (1973). The effect of chronic metabolic acidosis and alkalosis on
803 ventilation during exercise and hypoxia. *Respir Physiol* **17**, 336–346.
- 804 Forster HV, Dempsey JA & Chosy LW (1975). Incomplete compensation of CSF [H⁺] in man
805 during acclimatization to high altitude (4,300 m). *J Appl Physiol* **38**, 1067–1072.
- 806 Friberg L, Kastrup J, Rizzi D, Jensen JB & Lassen NA (1990). Cerebral blood flow and end-tidal
807 PCO₂ during prolonged acetazolamide treatment in humans. *American Journal of*
808 *Physiology-Legacy Content* **258**, H954–H959.
- 809 Gesell R, Krueger H, Gorham G & Bernthal T (1930). The regulation of respiration: A study of
810 the correlation of numerous factors of respiratory control following intravenous injection of
811 sodium bicarbonate. *American Journal of Physiology-Legacy Content* **94**, 387–401.
- 812 Gledhill N, Beirne GJ & Dempsey JA (1975). Renal response to short-term hypocapnia in man.
813 *Kidney Int* **8**, 376–384.
- 814 Hasan FM & Kazemi H (1976). Dual contribution theory of regulation of CSF HCO₃ in
815 respiratory acidosis. *J Appl Physiol* **40**, 559–567.
- 816 Hasselbalch KA (1916). *Die Berechnung der Wasserstoffzahl des Blutes aus der freien und*
817 *gebundenen Kohlensäure desselben, und die Sauerstoffbindung des Blutes als Funktion der*
818 *Wasserstoffzahl*. Springer.

ACID-BASE BALANCE AND CEREBRAL BLOOD FLOW AT HIGH-ALTITUDE

- 819 Hauge A, Nicolaysen G & Thoresen M (1983). Acute effects of acetazolamide on cerebral blood
820 flow in man. *Acta Physiol Scand* **117**, 233–239.
- 821 Hesser CM (1949). Central and chemoreflex components in the respiratory activity during acid-
822 base displacements in the blood. *Acta Physiol Scand*.
- 823 Hoiland RL, Fisher JA & Ainslie PN (2019). Regulation of the Cerebral Circulation by Arterial
824 Carbon Dioxide. *Compr Physiol* **9**, 1101–1154.
- 825 Hoiland RL, Howe CA, Coombs GB & Ainslie PN (2018). Ventilatory and cerebrovascular
826 regulation and integration at high-altitude. *Clin Auton Res* **28**, 423–435.
- 827 Hornbein TF & Pavlin EG (1975). Distribution of H⁺ and HCO₃⁻ between CSF and blood
828 during respiratory alkalosis in dogs. *American Journal of Physiology-Legacy Content* **228**,
829 1149–1154.
- 830 Hosford PS, Wells JA, Ruminot I, Christie IN, Theparambil SM, Hadjihambi A, Barros LF,
831 Lythgoe MF & Gourine AV (2021). CO₂ signalling mediates neurovascular coupling in the
832 cerebral cortex. *bioRxiv*2020.12.31.424942.
- 833 Howe CA, Caldwell HG, Carr J, Nowak-Flück D, Ainslie PN & Hoiland RL (2020).
834 Cerebrovascular reactivity to carbon dioxide is not influenced by variability in the
835 ventilatory sensitivity to carbon dioxide. *Exp Physiol* **105**, 904–915.
- 836 Huckstepp RTR, id Bihi R, Eason R, Spyer KM, Dicke N, Willecke K, Marina N, Gourine AV &
837 Dale N (2010). Connexin hemichannel-mediated CO₂-dependent release of ATP in the
838 medulla oblongata contributes to central respiratory chemosensitivity. *J Physiol* **588**, 3901–
839 3920.
- 840 Ito H, Kanno I, Ibaraki M, Hatazawa J & Miura S (2003). Changes in human cerebral blood flow
841 and cerebral blood volume during hypercapnia and hypocapnia measured by positron
842 emission tomography. *Journal of Cerebral Blood Flow & Metabolism* **23**, 665–670.
- 843 Ito H, Yokoyama I, Iida H, Kinoshita T, Hatazawa J, Shimosegawa E, Okudera T & Kanno I
844 (2000). Regional differences in cerebral vascular response to PaCO₂ changes in humans
845 measured by positron emission tomography. *Journal of Cerebral Blood Flow & Metabolism*
846 **20**, 1264–1270.
- 847 Jensen JB, Wright AD, Lassen NA, Harvey TC, Winterborn MH, Raichle ME & Bradwell AR
848 (1990). Cerebral blood flow in acute mountain sickness. *Journal of Applied Physiology* **69**,
849 430–433.
- 850 Kazemi H & Choma L (1977). H⁺ transport from CNS in hypercapnia and regulation of CSF
851 [HCO₃⁻]. *J Appl Physiol Respir Environ Exerc Physiol* **42**, 667–672.
- 852 Kazemi H, Weyne J, VanLeuven F & Leusen I (1976). The CSF HCO₃⁻ increase in hypercapnia
853 relationship to HCO₃⁻, glutamate, glutamine and NH₃ in brain. *Respir Physiol* **28**, 387–401.

- 854 Kety SS & Schmidt CF (1948). The effects of altered arterial tensions of carbon dioxide and
855 oxygen on cerebral blood flow and cerebral oxygen consumption of normal young men.
856 *Journal of Clinical Investigation* **27**, 484–492.
- 857 Kollef M & Isakow W (2012). *The Washington Manual of Critical Care*. Wolters Kluwer
858 Health.
- 859 Kontos HA, Raper AJ & Patterson JL (1977a). Analysis of vasoactivity of local pH, PCO₂ and
860 bicarbonate on pial vessels. *Stroke* **8**, 358–360.
- 861 Kontos HA, Wei EP, Raper AJ & Patterson JL Jr (1977b). Local mechanism of CO₂ action of
862 cat pial arterioles. *Stroke* **8**, 226–229.
- 863 Krapf R, Beeler I, Hertner D & Hulter HN (1991). Chronic respiratory alkalosis. The effect of
864 sustained hyperventilation on renal regulation of acid-base equilibrium. *N Engl J Med* **324**,
865 1394–1401.
- 866 Kronenberg RS & Cain SM (1968). Effects of acetazolamide and hypoxia on cerebrospinal fluid
867 bicarbonate. *J Appl Physiol* **24**, 17–20.
- 868 Lambertsen CJ, Semple SJG, Smyth MG & Gelfand R (1961). H⁺ and pCO₂ as chemical factors
869 in respiratory and cerebral circulatory control. *Journal of Applied Physiology* **16**, 473–484.
- 870 Lassen NA (1968). Brain extracellular pH: the main factor controlling cerebral blood flow.
871 *Scandinavian Journal of Clinical and Laboratory Investigation* **22**, 247–251.
- 872 Lassen NA, Friberg L, Kastrup J, Rizzi D & Jensen JJ (1987). Effects of acetazolamide on
873 cerebral blood flow and brain tissue oxygenation. *Postgrad Med J* **63**, 185–187.
- 874 Low EV, Avery AJ, Gupta V, Schedlbauer A & Grocott MPW (2012). Identifying the lowest
875 effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic
876 review and meta-analysis. *BMJ* **345**, e6779–e6779.
- 877 Lucas SJE, Burgess KR, Thomas KN, Donnelly J, Peebles KC, Lucas RAI, Fan J-L, Cotter JD,
878 Basnyat R & Ainslie PN (2011). Alterations in cerebral blood flow and cerebrovascular
879 reactivity during 14 days at 5050 m. *J Physiol (Lond)* **589**, 741–753.
- 880 Lumb AB (2016). *Nunn's Applied Respiratory Physiology eBook*, 8 edn.
- 881 Mathew L, Gopinath PM, Purkayastha SS, Gupta Sen J & Nayar HS (1983). Chemoreceptor
882 sensitivity in adaptation to high altitude. *Aviat Space Environ Med* **54**, 121–126.
- 883 Mitchell RA, Carman CT, Severinghaus JW, Richardson BW, Singer MM & Shnider S (1965).
884 Stability of cerebrospinal fluid pH in chronic acid-base disturbances in blood. *J Appl Physiol*
885 **20**, 443–452.
- 886 Møller K, Paulson OB, Hornbein TF, Colier WNJM, Paulson AS, Roach RC, Holm S &
887 Knudsen GM (2002). Unchanged cerebral blood flow and oxidative metabolism after

ACID-BASE BALANCE AND CEREBRAL BLOOD FLOW AT HIGH-ALTITUDE

- 888 acclimatization to high altitude. *Journal of Cerebral Blood Flow & Metabolism* **22**, 118–
889 126.
- 890 Nattie EE & Romer L (1978). CSF HCO₃⁻ regulation in isosmotic conditions: the role of brain
891 PCO₂ and plasma HCO₃⁻. *Respir Physiol* **33**, 177–198.
- 892 Pappenheimer JR (1970). *Transport of HCO₃⁻ between brain and blood. In: Capillary*
893 *Permeability, Alfred Benzon Symposium II*. Crone C & Lassen NA. Copenhagen,
894 Denmark.
- 895 Parati G, Revera M, Giuliano A, Faini A, Bilo G, Gregorini F, Lisi E, Salerno S, Lombardi C,
896 Ramos Becerra CG, Mancina G & Salvi P (2013). Effects of acetazolamide on central blood
897 pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposure.
898 *Eur Heart J* **34**, 759–766.
- 899 Pickkers P, Hughes AD, Russel FG, Thien T & Smits P (2001). In vivo evidence for K(Ca)
900 channel opening properties of acetazolamide in the human vasculature. *Br J Pharmacol* **132**,
901 443–450.
- 902 Posner JB & Plum F (1960). The toxic effects of carbon dioxide and acetazolamide in hepatic
903 encephalopathy. *Journal of Clinical Investigation* **39**, 1246–1258.
- 904 Ramsay SC, Murphy K, Shea SA, Friston KJ, Lammertsma AA, Clark JC, Adams L, Guz A &
905 Frackowiak RS (1993). Changes in global cerebral blood flow in humans: effect on regional
906 cerebral blood flow during a neural activation task. *J Physiol (Lond)* **471**, 521–534.
- 907 Richalet J-P, Rivera M, Bouchet P, Chirinos E, Onnen I, Petitjean O, Bienvenu A, Lasne F,
908 Moutereau S & León-Velarde F (2005). Acetazolamide: a treatment for chronic mountain
909 sickness. *Am J Respir Crit Care Med* **172**, 1427–1433.
- 910 Ritchie ND, Baggott AV & Andrew Todd WT (2012). Acetazolamide for the prevention of acute
911 mountain sickness--a systematic review and meta-analysis. *J Travel Med* **19**, 298–307.
- 912 Ritschel WA, Paulos C, Arancibia A, Agrawal MA, Wetzelsberger KM & Lückner PW (1998).
913 Pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure
914 to high altitude. *J Clin Pharmacol* **38**, 533–539.
- 915 Robin ED, Whaley RD, Crump CH, Bickelmann AG & Travis DM (1958). Acid-base relations
916 between spinal fluid and arterial blood with special reference to control of ventilation. *J Appl*
917 *Physiol* **13**, 385–392.
- 918 Rupp T, Esteve F, Bouzat P, Lundby C, Perrey S, Levy P, Robach P & Verges S (2014).
919 Cerebral hemodynamic and ventilatory responses to hypoxia, hypercapnia, and hypocapnia
920 during 5 days at 4,350 m. *J Cereb Blood Flow Metab* **34**, 52–60.
- 921 Schieve JF & Wilson WP (1953). The changes in cerebral vascular resistance of man in
922 experimental alkalosis and acidosis. *Journal of Clinical Investigation* **32**, 33–38.

ACID-BASE BALANCE AND CEREBRAL BLOOD FLOW AT HIGH-ALTITUDE

- 923 Severinghaus JW (1965). *Electrochemical gradients for hydrogen and bicarbonate ions across*
 924 *the blood-CSF barrier in response to acid-base balance changes. In: Cerebrospinal Fluid*
 925 *and the Regulation of Ventilation*. Brooks CM, Kao FF & Lloyd BB. Oxford, UK.
- 926 Severinghaus JW & Lassen N (1967). Step hypocapnia to separate arterial from tissue PCO₂ in
 927 the regulation of cerebral blood flow. *Circulation Research* **20**, 272–278.
- 928 Severinghaus JW, Mitchell RA, Richardson BW & Singer MM (1963). Respiratory control at
 929 high altitude suggesting active transport regulation of CSF pH. *J Appl Physiol* **18**, 1155–
 930 1166.
- 931 Shibata H, Saitoh Y, Takahashi H & Okubo T (1976). The apparent buffer value of cerebrospinal
 932 fluid in acute hypercapnia. *Bull Eur Physiopathol Respir* **12**, 297–315.
- 933 Shock NW & Hastings AB (1935). Studies of the acid-base balance of the blood. IV.
 934 Characterization and interpretation of displacement of the acid-base balance. *J Biol Chem*.
- 935 Siesjö BK (1972). Symposium on acid-base homeostasis. The regulation of cerebrospinal fluid
 936 pH. *Kidney Int* **1**, 360–374.
- 937 Singer RB, Deering RC & Clark JK (1956). The acute effects in man of a rapid intravenous
 938 infusion of hypertonic sodium bicarbonate solution. II. Changes in respiration and output of
 939 carbon dioxide. *Journal of Clinical Investigation* **35**, 245–253.
- 940 Skinhoj E (1966). Regulation of cerebral blood flow as a single function of the interstitial pH in
 941 the brain. A hypothesis. *Acta Neurol Scand* **42**, 604–607.
- 942 Smith KJ, Wong LE, Eves ND, Koelwyn GJ, Smirl JD, Willie CK & Ainslie PN (2012).
 943 Regional cerebral blood flow distribution during exercise: Influence of oxygen. *Respiratory*
 944 *Physiology & Neurobiology* **184**, 97–105.
- 945 Smith KJ, MacLeod D, Willie CK, Lewis NCS, Hoiland RL, Ikeda K, Tymko MM, Donnelly J,
 946 Day TA, MacLeod N, Lucas SJE & Ainslie PN (2014). Influence of high altitude on cerebral
 947 blood flow and fuel utilization during exercise and recovery. **592**, 5507–5527.
- 948 Swenson ER (2014). Carbonic anhydrase inhibitors and high altitude illnesses. *Subcell Biochem*
 949 **75**, 361–386.
- 950 Swenson ER & Hughes JM (1993). Effects of acute and chronic acetazolamide on resting
 951 ventilation and ventilatory responses in men. *Journal of Applied Physiology* **74**, 230–237.
- 952 Teppema LJ, van Dorp ELA & Dahan A (2010). Arterial [H⁺] and the ventilatory response to
 953 hypoxia in humans: influence of acetazolamide-induced metabolic acidosis. *Am J Physiol*
 954 *Lung Cell Mol Physiol* **298**, L89–L95.
- 955 Thomas KN, Lewis NCS, Hill BG & Ainslie PN (2015). Technical recommendations for the use
 956 of carotid duplex ultrasound for the assessment of extracranial blood flow. *Am J Physiol*
 957 *Regul Integr Comp Physiol* **309**, 1–7.

ACID-BASE BALANCE AND CEREBRAL BLOOD FLOW AT HIGH-ALTITUDE

- 958 Tremblay JC, Lovering AT, Ainslie PN, Stenbridge M, Burgess KR, Bakker A, Donnelly J,
959 Lucas SJE, Lewis NCS, Dominelli PB, Henderson WR, Dominelli GS, Sheel AW & Foster
960 GE (2015). Hypoxia, not pulmonary vascular pressure, induces blood flow through
961 intrapulmonary arteriovenous anastomoses. *J Physiol (Lond)* **593**, 723–737.
- 962 Tymko MM, Ainslie PN, Macleod DB, Willie CK & Foster GE (2015). End tidal-to-arterial CO₂
963 and O₂ gas gradients at low- and high-altitude during dynamic end-tidal forcing. *Am J*
964 *Physiol Regul Integr Comp Physiol* **308**, R895–R906.
- 965 Tymko MM, Hoiland RL, Kuca T, Boulet LM, Tremblay JC, Pinsky BK, Williams AM & Foster
966 GE (2016). Measuring the human ventilatory and cerebral blood flow response to CO₂: a
967 technical consideration for the end-tidal-to-arterial gas gradient. *J Appl Physiol* **120**, 282–
968 296.
- 969 Vorstrup S, Henriksen L & Paulson OB (1984). Effect of acetazolamide on cerebral blood flow
970 and cerebral metabolic rate for oxygen. *Journal of Clinical Investigation* **74**, 1634–1639.
- 971 Wahl M, Deetjen P, Thürau K, Ingvar DH & Lassen NA (1970). Micropuncture evaluation of the
972 importance of perivascular pH for the arteriolar diameter on the brain surface. *Pflügers Arch*
973 **316**, 152–163.
- 974 Weiskopf RB, Gabel RA & Fencel V (1976). Alkaline shift in lumbar and intracranial CSF in man
975 after 5 days at high altitude. *J Appl Physiol* **41**, 93–97.
- 976 West JB & Luks AM (2020). *West's Respiratory Physiology*, 11 edn.
- 977 Wichser J & Kazemi H (1975). CSF bicarbonate regulation in respiratory acidosis and alkalosis.
978 *J Appl Physiol* **38**, 504–511.
- 979 Willie CK, Colino FL, Bailey DM, Tzeng YC, Binsted G, Jones LW, Haykowsky MJ, Bellapart
980 J, Ogoh S, Smith KJ, Smirl JD, Day TA, Lucas SJ, Eller LK & Ainslie PN (2011). Utility of
981 transcranial Doppler ultrasound for the integrative assessment of cerebrovascular function. *J*
982 *Neurosci Methods* **196**, 221–237.
- 983 Willie CK, Macleod DB, Shaw AD, Smith KJ, Tzeng YC, Eves ND, Ikeda K, Graham J, Lewis
984 NC, Day TA & Ainslie PN (2012). Regional brain blood flow in man during acute changes
985 in arterial blood gases. *J Physiol (Lond)* **590**, 3261–3275.
- 986 Willie CK, Macleod DB, Smith KJ, Lewis NC, Foster GE, Ikeda K, Hoiland RL & Ainslie PN
987 (2015). The Contribution of Arterial Blood Gases in Cerebral Blood Flow Regulation and
988 Fuel Utilization in Man at High Altitude:.. *Journal of Cerebral Blood Flow & Metabolism*
989 **35**, 873–881.
- 990 Willie CK, Tzeng YC, Fisher JA & Ainslie PN (2014). Integrative regulation of human brain
991 blood flow. *J Physiol (Lond)* **592**, 841–859.

- 992 Wolff HG & Lennox WG (1930). CEREBRAL CIRCULATION: XII. THE EFFECT ON PIAL
993 VESSELS OF VARIATIONS IN THE OXYGEN AND CARBON DIOXIDE CONTENT
994 OF THE BLOOD. *Archives of Neurology & Psychiatry* **23**, 1097–1120.
- 995 Woodman RJ, Playford DA, Watts GF, Cheetham C, Reed C, Taylor RR, Puddey IB, Beilin LJ,
996 Burke V, Mori TA & Green D (2001). Improved analysis of brachial artery ultrasound using
997 a novel edge-detection software system. *Journal of Applied Physiology* **91**, 929–937.

ACID-BASE BALANCE AND CEREBRAL BLOOD FLOW AT HIGH-ALTITUDE

Table 1. Arterial blood gas and acid-base parameters at rest during control, acetazolamide, and sodium bicarbonate infusion conditions at sea level (344 m) and high-altitude (5,050 m)

| | | Control | ACZ | ACZ+HCO ₃ ⁻ | <i>P-Values</i> | | |
|---|----|------------------------------|-----------------------------|------------------------------------|---------------------|---------------------|-------------------------|
| | | | | | <i>Trial</i> | <i>Altitude</i> | <i>Trial × Altitude</i> |
| pH | SL | 7.42 ± 0.01 ^b | 7.36 ± 0.03 | 7.44 ± 0.02 ^b | P < 0.001 | P = 0.002 | P = 0.117 |
| | HA | 7.47 ± 0.07 ^b | 7.40 ± 0.02 | 7.44 ± 0.02 ^b | | | |
| [H ⁺] (nM) | SL | 37.9 ± 1.3 ^b | 44.0 ± 3.2 | 36.6 ± 2.1 ^b | P < 0.001 | P = 0.005 | P = 0.172 |
| | HA | 34.4 ± 6.8 ^b | 39.8 ± 2.1 | 36.0 ± 1.6 ^b | | | |
| [HCO ₃ ⁻] (mEq·l ⁻¹) | SL | 25.5 ± 1.6 ^{\$,+} | 19.2 ± 0.9 ^{a,%} | 24.6 ± 1.2 ^{a,b,\$,&} | P < 0.001 | P < 0.001 | P = 0.002 |
| | HA | 17.4 ± 2.5 ^{\$,+} | 13.5 ± 1.3 ^{a,%} | 15.9 ± 1.2 ^{a,b,\$,&} | | | |
| Base Excess (mEq·l ⁻¹) | SL | 1.3 ± 1.4 ^{b,\$,+} | -5.4 ± 0.8 [%] | 0.7 ± 1.2 ^{b,\$,&} | P < 0.001 | P < 0.001 | P = 0.025 |
| | HA | -6.3 ± 3.6 ^{b,\$,+} | -11.3 ± 1.4 [%] | -8.2 ± 1.2 ^{b,\$,&} | | | |
| PaCO ₂ (mmHg) | SL | 40.1 ± 3.6 | 35.2 ± 3.5 ^a | 37.1 ± 2.9 | P < 0.001 | P < 0.001 | P = 0.073 |
| | HA | 23.7 ± 1.8 | 21.7 ± 2.1 ^a | 23.2 ± 2.2 | | | |
| PaO ₂ (mmHg) | SL | 94 ± 13 | 102 ± 7 ^a | 98 ± 9 | P = 0.005 | P < 0.001 | P = 0.703 |
| | HA | 43 ± 2 | 48 ± 2 ^a | 46 ± 3 | | | |
| SaO ₂ (%) | SL | 97.0 ± 1.6 ⁺ | 97.8 ± 0.5 ^{a,%} | 97.5 ± 0.7 ^{a,&} | P < 0.001 | P < 0.001 | P = 0.038 |
| | HA | 82.7 ± 2.2 ⁺ | 85.0 ± 2.2 ^{a,#,%} | 85.0 ± 2.4 ^{a,#,&} | | | |
| CaO ₂ (mL·dL ⁻¹) | SL | 19.8 ± 0.7 ^{\$,+} | 21.0 ± 0.5 ^{a,%} | 19.7 ± 1.0 ^{a,b,\$} | P < 0.001 | P < 0.001 | P = 0.003 |
| | HA | 17.5 ± 1.1 ⁺ | 19.3 ± 1.2 ^{a,#,%} | 19.1 ± 0.5 ^{a,b,#} | | | |
| [Hb] (g·dL ⁻¹) | SL | 15.0 ± 0.7 ^{\$,+} | 15.8 ± 0.4 ^{a,%} | 14.9 ± 0.8 ^{a,b,\$,&} | P < 0.001 | P < 0.001 | P = 0.024 |
| | HA | 15.7 ± 1.2 ⁺ | 16.9 ± 1.1 ^{a,#,%} | 16.6 ± 0.9 ^{a,b,#,&} | | | |

Abbreviations: Hydrogen concentration, [H⁺]; bicarbonate concentration, [HCO₃⁻]; arterial carbon dioxide tension, PaCO₂; arterial oxygen tension, PaO₂; arterial oxygen saturation, SaO₂; arterial oxygen content, CaO₂; hemoglobin concentration, [Hb]. Trial main effect pairwise comparisons: ^aP < 0.05 versus control; ^bP < 0.05 versus ACZ. Trial × altitude interaction pairwise comparisons: [#]P < 0.05 versus control within altitude; ^{\$}P < 0.05 versus ACZ within altitude; ⁺P < 0.05 versus control between altitudes; [%]P < 0.05 versus ACZ between altitudes; [&]P < 0.05 versus ACZ+HCO₃⁻ between altitudes. Data are mean ± SD. Sample sizes: n=7 for all three trials at sea level (SL), n=10 for the control and ACZ trials at high-altitude (HA), and n=5 for the ACZ+HCO₃⁻ trial at HA.

ACID-BASE BALANCE AND CEREBRAL BLOOD FLOW AT HIGH-ALTITUDE

Table 2. Cardiorespiratory and cerebrovascular parameters at rest during control, acetazolamide, and sodium bicarbonate infusion conditions at sea level (344 m) and high-altitude (5,050 m)

| | | Control | ACZ | ACZ+HCO ₃ ⁻ | <i>P-Values</i> | | |
|---|----|----------------------|---------------------|-----------------------------------|------------------|---------------------|-------------------------|
| | | | | | <i>Trial</i> | <i>Altitude</i> | <i>Trial × Altitude</i> |
| \dot{V}_E (L·min ⁻¹) | SL | 11.5 ± 2.2 | 11.8 ± 1.4 | 12.0 ± 1.3 | P = 0.434 | P < 0.001 | P = 0.813 |
| | HA | 17.6 ± 3.7 | 19.1 ± 1.5 | 18.7 ± 3.6 | | | |
| V_T (L) | SL | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 | P = 0.499 | P < 0.001 | P = 0.085 |
| | HA | 1.2 ± 0.4 | 1.1 ± 0.1 | 1.3 ± 0.2 | | | |
| f_R (BPM) | SL | 14 ± 3 | 14 ± 2 [%] | 16 ± 2 | P = 0.663 | P = 0.026 | P = 0.046 |
| | HA | 16 ± 5 | 18 ± 2 [%] | 15 ± 2 | | | |
| HR (bpm) | SL | 59 ± 6 | 60 ± 9 | 60 ± 10 | P = 0.126 | P < 0.001 | P = 0.066 |
| | HA | 72 ± 12 | 76 ± 14 | 70 ± 14 | | | |
| MAP (mmHg) | SL | 86 ± 8 ^b | 82 ± 9 | 85 ± 11 ^b | P = 0.004 | P < 0.001 | P = 0.083 |
| | HA | 105 ± 7 ^b | 92 ± 7 | 102 ± 7 ^b | | | |
| CDO ₂ (mL·min ⁻¹) | SL | 88 ± 43 | 89 ± 31 | 91 ± 42 | P = 0.678 | P = 0.009 | P = 0.627 |
| | HA | 120 ± 43 | 125 ± 38 | 108 ± 13 | | | |
| $gCBF$ (mL·min ⁻¹) | SL | 450 ± 204 | 423 ± 152 | 460 ± 204 | P = 0.356 | P < 0.001 | P = 0.295 |
| | HA | 683 ± 225 | 647 ± 189 | 607 ± 120 | | | |
| $gCBF_{cvc}$ (mL·min ⁻¹ ·mmHg ⁻¹) | SL | 5.38 ± 2.25 | 5.11 ± 1.77 | 5.45 ± 2.28 | P = 0.583 | P = 0.022 | P = 0.218 |
| | HA | 6.54 ± 2.02 | 7.15 ± 1.88 | 5.92 ± 0.99 | | | |

Abbreviations: Ventilation, \dot{V}_E ; tidal volume, V_T ; respiratory frequency, f_R ; breaths per minute, BPM; heart rate, HR; beats per minute, bpm; mean arterial pressure, MAP; cerebral oxygen delivery, CDO₂; global cerebral blood flow, $gCBF$; global cerebrovascular conductance, $gCBF_{cvc}$. Trial main effect pairwise comparisons: ^bP < 0.05 versus ACZ. Trial × altitude interaction pairwise comparisons: [%]P < 0.05 versus ACZ between altitudes. Data are mean ± SD for n=11 at sea level (SL) and n=10 at high-altitude (HA).

ACID-BASE BALANCE AND CEREBRAL BLOOD FLOW AT HIGH-ALTITUDE

Table 3. Relative cerebrovascular CO₂ reactivity during control, acetazolamide, and sodium bicarbonate infusion conditions at sea level (344 m) and high-altitude (5,050 m)

| | | Control | ACZ | ACZ+HCO ₃ ⁻ | <i>P-Values</i> | | |
|----------------------------|----|------------------------|------------------------|-----------------------------------|------------------|---------------------|-------------------------|
| Reactivity (Δ% per Δ mmHg) | | | | | <i>Trial</i> | <i>Altitude</i> | <i>Trial × Altitude</i> |
| MCA _v hypo- | SL | 3.0 ± 0.5 | 2.9 ± 0.4 | 3.3 ± 0.5 | P = 0.276 | P < 0.001 | P = 0.413 |
| | HA | 4.2 ± 0.8 | 4.0 ± 0.5 | 4.2 ± 0.5 | | | |
| MCA _v hyper- | SL | 4.7 ± 1.1 | 3.7 ± 1.1 ^a | 3.2 ± 1.0 ^a | P = 0.005 | P < 0.001 | P = 0.424 |
| | HA | 7.1 ± 1.6 | 6.0 ± 1.0 ^a | 6.4 ± 1.5 ^a | | | |
| MCA _{CVC} hypo- | SL | 2.9 ± 0.5 ⁺ | 2.8 ± 0.3 [%] | 3.2 ± 0.6 | P = 0.539 | P < 0.001 | P = 0.045 |
| | HA | 3.7 ± 0.7 ⁺ | 3.9 ± 0.4 [%] | 3.6 ± 0.6 | | | |
| MCA _{CVC} hyper- | SL | 2.8 ± 1.0 | 2.5 ± 0.7 | 2.1 ± 0.7 ^{&} | P = 0.252 | P = 0.018 | P = 0.030 |
| | HA | 3.1 ± 1.2 | 2.6 ± 0.7 | 3.4 ± 1.0 ^{&} | | | |
| PCA _v hypo- | SL | 2.7 ± 0.3 ⁺ | 3.0 ± 0.5 [%] | 3.2 ± 0.8 ^{&} | P = 0.805 | P < 0.001 | P = 0.006 |
| | HA | 4.4 ± 0.8 ⁺ | 4.2 ± 0.7 [%] | 3.9 ± 0.5 ^{&} | | | |
| PCA _v hyper- | SL | 4.1 ± 1.2 | 3.9 ± 1.5 | 3.3 ± 1.2 | P = 0.073 | P < 0.001 | P = 0.470 |
| | HA | 7.9 ± 2.2 | 6.7 ± 0.8 | 6.6 ± 2.2 | | | |
| PCA _{CVC} hypo- | SL | 2.6 ± 0.3 ⁺ | 2.9 ± 0.5 [%] | 3.1 ± 0.8 | P = 0.081 | P < 0.001 | P = 0.001 |
| | HA | 3.9 ± 0.7 ⁺ | 4.1 ± 0.5 [%] | 3.2 ± 0.7 ^{#,\$} | | | |
| PCA _{CVC} hyper- | SL | 2.4 ± 1.1 | 2.7 ± 1.2 | 2.2 ± 0.9 | P = 0.849 | P = 0.002 | P = 0.418 |
| | HA | 3.7 ± 1.6 | 3.1 ± 0.6 | 3.4 ± 1.4 | | | |

Abbreviations: Middle cerebral artery blood velocity, MCA_v; Posterior cerebral artery blood velocity, PCA_v; cerebrovascular conductance, CVC; hypocapnia, hypo-; hypercapnia, hyper-. Trial main effect pairwise comparisons: ^aP < 0.05 versus control. Trial × altitude interaction pairwise comparisons: [#]P < 0.05 versus control within altitude; ^{\$}P < 0.05 versus ACZ within altitude; ⁺P < 0.05 versus control between altitudes; [%]P < 0.05 versus ACZ between altitudes; [&]P < 0.05 versus ACZ+HCO₃⁻ between altitudes. Data are mean ± SD. Sample sizes: SL control, n=10; SL ACZ, n=11; SL ACZ+HCO₃⁻, n=11; HA control, n=10; HA ACZ, n=9; HA ACZ+HCO₃⁻, n=9.

ACID-BASE BALANCE AND CEREBRAL BLOOD FLOW AT HIGH-ALTITUDE

Table 4. Absolute cerebrovascular CO₂ reactivity during control, acetazolamide, and sodium bicarbonate infusion conditions at sea level (344 m) and high-altitude (5,050 m)

| | | Control | ACZ | ACZ+HCO ₃ ⁻ | <i>P-Values</i> | | |
|--------------------------------|----|------------------------|------------------------|-----------------------------------|------------------|---------------------|-------------------------|
| Reactivity (Δ cm/s per Δ mmHg) | | | | | <i>Trial</i> | <i>Altitude</i> | <i>Trial × Altitude</i> |
| MCA _v hypo- | SL | 2.0 ± 0.4 ⁺ | 2.1 ± 0.4 | 2.7 ± 0.7 ^{#, \$} | P = 0.073 | P = 0.028 | P = 0.016 |
| | HA | 2.8 ± 0.8 ⁺ | 2.6 ± 0.7 | 2.7 ± 0.6 | | | |
| MCA _v hyper- | SL | 3.1 ± 0.7 | 2.6 ± 0.8 ^a | 2.5 ± 0.6 ^a | P = 0.004 | P < 0.001 | P = 0.699 |
| | HA | 4.7 ± 1.1 | 3.8 ± 0.7 ^a | 3.6 ± 1.1 ^a | | | |
| MCA _{CVC} hypo- | SL | 0.02 ± 0.00 | 0.03 ± 0.01 | 0.03 ± 0.01 ^{#, &} | P = 0.081 | P = 0.127 | P = 0.012 |
| | HA | 0.02 ± 0.01 | 0.03 ± 0.01 | 0.02 ± 0.01 ^{&} | | | |
| MCA _{CVC} hyper- | SL | 0.02 ± 0.01 | 0.02 ± 0.01 | 0.02 ± 0.01 | P = 0.498 | P = 0.037 | P = 0.911 |
| | HA | 0.02 ± 0.01 | 0.02 ± 0.00 | 0.02 ± 0.01 | | | |
| PCA _v hypo- | SL | 1.3 ± 0.5 | 1.4 ± 0.4 | 1.7 ± 0.7 | P = 0.447 | P = 0.017 | P = 0.056 |
| | HA | 2.0 ± 0.5 | 1.8 ± 0.5 | 1.8 ± 0.5 | | | |
| PCA _v hyper- | SL | 2.0 ± 0.8 | 1.8 ± 0.7 | 1.7 ± 0.6 | P = 0.084 | P < 0.001 | P = 0.427 |
| | HA | 3.6 ± 1.1 | 2.9 ± 0.8 | 2.9 ± 0.7 | | | |
| PCA _{CVC} hypo- | SL | 0.01 ± 0.00 | 0.02 ± 0.00 | 0.02 ± 0.01 ^{#, &} | P = 0.168 | P = 0.385 | P = 0.015 |
| | HA | 0.02 ± 0.00 | 0.02 ± 0.01 | 0.01 ± 0.00 ^{&} | | | |
| PCA _{CVC} hyper- | SL | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 | P = 0.940 | P = 0.199 | P = 0.577 |
| | HA | 0.02 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.00 | | | |

Abbreviations: Middle cerebral artery blood velocity, MCA_v; Posterior cerebral artery blood velocity, PCA_v; cerebrovascular conductance, CVC; hypocapnia, hypo-; hypercapnia, hyper-. Trial main effect pairwise comparisons: ^aP < 0.05 versus control. Trial × altitude interaction pairwise comparisons: [#]P < 0.05 versus control within altitude; ^{\$}P < 0.05 versus ACZ within altitude; ⁺P < 0.05 versus control between altitudes; [&]P < 0.05 versus ACZ+HCO₃⁻ between altitudes. Data are mean ± SD. Sample sizes: SL control, n=10; SL ACZ, n=11; SL ACZ+HCO₃⁻, n=11; HA control, n=10; HA ACZ, n=9; HA ACZ+HCO₃⁻, n=9.





